ES2583231T3 - Derivados de triazol-triazina selectivos dependientes de inhibidores de ciclina quinasa - Google Patents
Derivados de triazol-triazina selectivos dependientes de inhibidores de ciclina quinasa Download PDFInfo
- Publication number
- ES2583231T3 ES2583231T3 ES13707008.2T ES13707008T ES2583231T3 ES 2583231 T3 ES2583231 T3 ES 2583231T3 ES 13707008 T ES13707008 T ES 13707008T ES 2583231 T3 ES2583231 T3 ES 2583231T3
- Authority
- ES
- Spain
- Prior art keywords
- triazine
- pyrazolo
- benzyl
- isopropyl
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000016736 Cyclin Human genes 0.000 title 1
- 108050006400 Cyclin Proteins 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- AYLVUAOVLCQQQD-UHFFFAOYSA-N triazine;2h-triazole Chemical class C1=CNN=N1.C1=CN=NN=C1 AYLVUAOVLCQQQD-UHFFFAOYSA-N 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 50
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- -1 2- (1 H -pyrazol-1-yl) benzyl Chemical group 0.000 claims description 496
- KCZIUKYAJJEIQG-UHFFFAOYSA-N 1,3,5-triazin-2-amine Chemical compound NC1=NC=NC=N1 KCZIUKYAJJEIQG-UHFFFAOYSA-N 0.000 claims description 202
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 46
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 29
- RHMAEMZNCNBNFR-UHFFFAOYSA-N 2-n-methyl-2-n-(2-morpholin-4-ylethyl)-8-propan-2-yl-4-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine Chemical compound N=1C(N(C)CCN2CCOCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 RHMAEMZNCNBNFR-UHFFFAOYSA-N 0.000 claims description 2
- XSFMNFYLWHPZIQ-UHFFFAOYSA-N n-pyrrolidin-1-ylacetamide Chemical compound CC(=O)NN1CCCC1 XSFMNFYLWHPZIQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000009366 Echinococcosis Diseases 0.000 claims 5
- 241000243985 Onchocerca volvulus Species 0.000 claims 4
- 208000028454 lice infestation Diseases 0.000 claims 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 3
- 206010059547 Cutaneous larva migrans Diseases 0.000 claims 3
- 201000003808 Cystic echinococcosis Diseases 0.000 claims 3
- 206010014096 Echinococciasis Diseases 0.000 claims 3
- 208000004204 Larva Migrans Diseases 0.000 claims 3
- 206010024229 Leprosy Diseases 0.000 claims 3
- 230000000968 intestinal effect Effects 0.000 claims 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 3
- 201000000317 pneumocystosis Diseases 0.000 claims 3
- 208000004881 Amebiasis Diseases 0.000 claims 2
- 206010001980 Amoebiasis Diseases 0.000 claims 2
- 206010009344 Clonorchiasis Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 208000008953 Cryptosporidiosis Diseases 0.000 claims 2
- 201000000077 Cysticercosis Diseases 0.000 claims 2
- 208000001490 Dengue Diseases 0.000 claims 2
- 206010012310 Dengue fever Diseases 0.000 claims 2
- 206010023076 Isosporiasis Diseases 0.000 claims 2
- 208000004554 Leishmaniasis Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 241001674048 Phthiraptera Species 0.000 claims 2
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims 2
- 208000000474 Poliomyelitis Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims 2
- 201000008680 babesiosis Diseases 0.000 claims 2
- 208000007456 balantidiasis Diseases 0.000 claims 2
- 208000025729 dengue disease Diseases 0.000 claims 2
- 208000003177 ocular onchocerciasis Diseases 0.000 claims 2
- 208000002042 onchocerciasis Diseases 0.000 claims 2
- KJMGACFYAQBTMJ-UHFFFAOYSA-N (1-methylpyrrolidin-3-yl) 8-propan-2-yl-4-[(2-pyrazol-1-ylphenyl)methylamino]pyrazolo[1,5-a][1,3,5]triazine-2-carboxylate Chemical compound N=1C(C(=O)OC2CN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 KJMGACFYAQBTMJ-UHFFFAOYSA-N 0.000 claims 1
- MGFLRUYNACZFMH-UHFFFAOYSA-N 2-(4-aminopiperidin-1-yl)-8-propan-2-yl-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(N2CCC(N)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 MGFLRUYNACZFMH-UHFFFAOYSA-N 0.000 claims 1
- FMLRQUYSBLLDJR-UHFFFAOYSA-N 2-(piperazin-1-ylmethyl)-8-propan-2-yl-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(CN2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 FMLRQUYSBLLDJR-UHFFFAOYSA-N 0.000 claims 1
- AGWTVSZIVNJBSU-UHFFFAOYSA-N 2-n-(2-piperazin-1-ylethyl)-8-propan-2-yl-4-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine Chemical compound N=1C(NCCN2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 AGWTVSZIVNJBSU-UHFFFAOYSA-N 0.000 claims 1
- OXXINTICAFIFQL-UHFFFAOYSA-N 2-n-(4-aminocyclohexyl)-8-propan-2-yl-4-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine Chemical compound N=1C(NC2CCC(N)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 OXXINTICAFIFQL-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000010370 Adenoviridae Infections Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 201000002045 Ancylostomiasis Diseases 0.000 claims 1
- 206010069517 Angiostrongylus infection Diseases 0.000 claims 1
- 208000033211 Ankylostomiasis Diseases 0.000 claims 1
- 208000008715 Ascaridida Infections Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 208000005740 Blastocystis Infections Diseases 0.000 claims 1
- 208000024952 Blastocystis infectious disease Diseases 0.000 claims 1
- 206010005098 Blastomycosis Diseases 0.000 claims 1
- 208000003508 Botulism Diseases 0.000 claims 1
- 206010006500 Brucellosis Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 241000242722 Cestoda Species 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 206010061041 Chlamydial infection Diseases 0.000 claims 1
- 208000035086 Chlamydophila Infections Diseases 0.000 claims 1
- 206010008631 Cholera Diseases 0.000 claims 1
- 241000223205 Coccidioides immitis Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 206010011409 Cross infection Diseases 0.000 claims 1
- 201000007336 Cryptococcosis Diseases 0.000 claims 1
- 241000221204 Cryptococcus neoformans Species 0.000 claims 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims 1
- 241000256054 Culex <genus> Species 0.000 claims 1
- 241000179197 Cyclospora Species 0.000 claims 1
- 208000011917 Cyclosporosis Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 241000935794 Dipylidium Species 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 208000010489 Entamoebiasis Diseases 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010061126 Escherichia infection Diseases 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 206010017543 Fungal skin infection Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010061192 Haemorrhagic fever Diseases 0.000 claims 1
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 claims 1
- 206010019375 Helicobacter infections Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 241000224421 Heterolobosea Species 0.000 claims 1
- 206010020376 Hookworm infection Diseases 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023927 Lassa fever Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000000932 Marburg Virus Disease Diseases 0.000 claims 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 claims 1
- HKAZXTQXMYDWTQ-UHFFFAOYSA-N N1(N=CC=C1)C1=C(CNC2=NC(=NC=3N2N=CC3C(C)C)CC3CNCCC3)C=CC=C1.C(N)(O)=O Chemical compound N1(N=CC=C1)C1=C(CNC2=NC(=NC=3N2N=CC3C(C)C)CC3CNCCC3)C=CC=C1.C(N)(O)=O HKAZXTQXMYDWTQ-UHFFFAOYSA-N 0.000 claims 1
- 206010056970 Naegleria infection Diseases 0.000 claims 1
- 208000007316 Neurocysticercosis Diseases 0.000 claims 1
- 241000275031 Nica Species 0.000 claims 1
- 208000001388 Opportunistic Infections Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 208000008071 Parvoviridae Infections Diseases 0.000 claims 1
- 206010057343 Parvovirus infection Diseases 0.000 claims 1
- 241000517324 Pediculidae Species 0.000 claims 1
- 241000233870 Pneumocystis Species 0.000 claims 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 241000282330 Procyon lotor Species 0.000 claims 1
- 241000517305 Pthiridae Species 0.000 claims 1
- 206010037688 Q fever Diseases 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 208000000705 Rift Valley Fever Diseases 0.000 claims 1
- 208000006723 Strongylida Infections Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 210000003001 amoeba Anatomy 0.000 claims 1
- 208000005067 anisakiasis Diseases 0.000 claims 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000003486 coccidioidomycosis Diseases 0.000 claims 1
- 201000002641 cyclosporiasis Diseases 0.000 claims 1
- 201000008167 cystoisosporiasis Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 208000000292 ehrlichiosis Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010014881 enterobiasis Diseases 0.000 claims 1
- 208000020612 escherichia coli infection Diseases 0.000 claims 1
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000001617 migratory effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- PZBGFUVQDAODLZ-ZYRTVQBDSA-N n-[[2-(methylsulfonimidoyl)phenyl]methyl]-2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1S(C)(=N)=O PZBGFUVQDAODLZ-ZYRTVQBDSA-N 0.000 claims 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000004441 taeniasis Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 201000002311 trypanosomiasis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 abstract description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 6
- 125000003342 alkenyl group Chemical group 0.000 abstract description 4
- 125000000304 alkynyl group Chemical group 0.000 abstract description 4
- 125000005605 benzo group Chemical group 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 2
- 229910052799 carbon Inorganic materials 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 150000001721 carbon Chemical group 0.000 abstract 10
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000001845 4 membered carbocyclic group Chemical group 0.000 abstract 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 abstract 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- JUXWUYWPUDKPSD-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazine Chemical compound N1=CN=CN2N=CC=C21 JUXWUYWPUDKPSD-UHFFFAOYSA-N 0.000 description 11
- XSCVJHCFMXPRNY-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine Chemical compound N1=C(N)N=C(N)N2N=CC=C21 XSCVJHCFMXPRNY-UHFFFAOYSA-N 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 6
- BWQJTDLHZWZABK-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide Chemical compound N1=C(C(=O)N)N=CN2N=CC=C21 BWQJTDLHZWZABK-UHFFFAOYSA-N 0.000 description 5
- OQHQOOLVQDEIGL-UHFFFAOYSA-N 2-methyl-2,7-diazaspiro[4.4]nonane Chemical compound C1N(C)CCC11CNCC1 OQHQOOLVQDEIGL-UHFFFAOYSA-N 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- BFAHRLVWYDSXIA-UHFFFAOYSA-N 1,8-diazaspiro[4.5]decane Chemical compound C1CCNC21CCNCC2 BFAHRLVWYDSXIA-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- SZUXYYIDZMHWDD-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound NC1=NC=NC2=CC=NN12 SZUXYYIDZMHWDD-UHFFFAOYSA-N 0.000 description 3
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 2
- RGADTVSBYVMPPB-UHFFFAOYSA-N 1,3,5-triazine-2-carboxamide Chemical compound NC(=O)C1=NC=NC=N1 RGADTVSBYVMPPB-UHFFFAOYSA-N 0.000 description 2
- XMFQVPUKWPFASE-UHFFFAOYSA-N 2-(2-piperidin-4-ylethoxy)-8-propan-2-yl-n-(quinolin-5-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C2=C(C(C)C)C=NN2C(NCC=2C3=CC=CN=C3C=CC=2)=NC=1OCCC1CCNCC1 XMFQVPUKWPFASE-UHFFFAOYSA-N 0.000 description 2
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- MILPMAMZKNOQRU-GOSISDBHSA-N n-(isoquinolin-8-ylmethyl)-2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C2=C(C(C)C)C=NN2C(NCC=2C3=CN=CC=C3C=CC=2)=NC=1O[C@@H]1CCCNC1 MILPMAMZKNOQRU-GOSISDBHSA-N 0.000 description 2
- RTKNBILYHOBGGQ-UHFFFAOYSA-N n-[(2-aminophenyl)methyl]-2-(azetidin-3-ylmethoxy)-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OCC2CNC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N RTKNBILYHOBGGQ-UHFFFAOYSA-N 0.000 description 2
- KLVKAHDMNHTZMZ-UHFFFAOYSA-N n-[2-[[[2-[2-[2-(dimethylamino)ethoxy]ethoxy]-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-yl]amino]methyl]phenyl]methanesulfonamide Chemical compound N=1C(OCCOCCN(C)C)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1NS(C)(=O)=O KLVKAHDMNHTZMZ-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- FOZDQDCJNLCOGM-QGZVFWFLSA-N 1-[2-[[[2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-yl]amino]methyl]phenyl]azetidin-2-one Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1CCC1=O FOZDQDCJNLCOGM-QGZVFWFLSA-N 0.000 description 1
- KKWCGZYJAOLYSQ-GOSISDBHSA-N 1-[2-[[[2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-yl]amino]methyl]phenyl]pyrrolidin-2-one Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1CCCC1=O KKWCGZYJAOLYSQ-GOSISDBHSA-N 0.000 description 1
- LXSHABMIUZYHDJ-UHFFFAOYSA-N 2,6-diazaspiro[4.5]decane Chemical compound C1NCCC21NCCCC2 LXSHABMIUZYHDJ-UHFFFAOYSA-N 0.000 description 1
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 1
- OXPIFHNJGOJJQZ-UHFFFAOYSA-N 2,7-diazaspiro[3.4]octane Chemical compound C1NCC11CNCC1 OXPIFHNJGOJJQZ-UHFFFAOYSA-N 0.000 description 1
- WYZZNMWIWHRXRM-UHFFFAOYSA-N 2,8-diazaspiro[4.5]decane Chemical compound C1NCCC21CCNCC2 WYZZNMWIWHRXRM-UHFFFAOYSA-N 0.000 description 1
- SEHHFRJVESDRRU-UHFFFAOYSA-N 2-(1-methylpiperidin-4-yl)oxy-8-propan-2-yl-n-[(2-propan-2-yloxyphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CC(C)OC1=CC=CC=C1CNC1=NC(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN12 SEHHFRJVESDRRU-UHFFFAOYSA-N 0.000 description 1
- VWGCKCKIYJUJKG-UHFFFAOYSA-N 2-(1-methylpiperidin-4-yl)oxy-8-propan-2-yl-n-[(2-thiophen-2-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CS1 VWGCKCKIYJUJKG-UHFFFAOYSA-N 0.000 description 1
- JMKVKXKEIXJYGC-UHFFFAOYSA-N 2-(1-methylpiperidin-4-yl)oxy-8-propan-2-yl-n-[[2-(trifluoromethyl)phenyl]methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C(F)(F)F JMKVKXKEIXJYGC-UHFFFAOYSA-N 0.000 description 1
- RRVCOCVHCKWXIU-UHFFFAOYSA-N 2-(1-methylpiperidin-4-yl)oxy-n-[(2-morpholin-4-ylphenyl)methyl]-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1CCOCC1 RRVCOCVHCKWXIU-UHFFFAOYSA-N 0.000 description 1
- WAIYAMJWORPJNE-UHFFFAOYSA-N 2-(1-methylpiperidin-4-yl)oxy-n-[(2-phenoxyphenyl)methyl]-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1OC1=CC=CC=C1 WAIYAMJWORPJNE-UHFFFAOYSA-N 0.000 description 1
- XEZVBSJQWRVWPA-UHFFFAOYSA-N 2-(2-azaspiro[3.3]heptan-7-yloxy)-8-propan-2-yl-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2C3(CNC3)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 XEZVBSJQWRVWPA-UHFFFAOYSA-N 0.000 description 1
- HIWUQQTVWKEVNU-QGZVFWFLSA-N 2-[(3r)-piperidin-3-yl]oxy-8-propan-2-yl-n-(quinolin-5-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C2=C(C(C)C)C=NN2C(NCC=2C3=CC=CN=C3C=CC=2)=NC=1O[C@@H]1CCCNC1 HIWUQQTVWKEVNU-QGZVFWFLSA-N 0.000 description 1
- CAJQAMBHYFGYMN-GOSISDBHSA-N 2-[(3r)-piperidin-3-yl]oxy-8-propan-2-yl-n-(quinolin-8-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C2=C(C(C)C)C=NN2C(NCC=2C3=NC=CC=C3C=CC=2)=NC=1O[C@@H]1CCCNC1 CAJQAMBHYFGYMN-GOSISDBHSA-N 0.000 description 1
- SGQXKMAREPYLFI-GOSISDBHSA-N 2-[(3r)-piperidin-3-yl]oxy-8-propan-2-yl-n-[(2-propan-2-yloxyphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CC(C)OC1=CC=CC=C1CNC1=NC(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN12 SGQXKMAREPYLFI-GOSISDBHSA-N 0.000 description 1
- XGKZTUXQLQHHRV-LJQANCHMSA-N 2-[(3r)-piperidin-3-yl]oxy-8-propan-2-yl-n-[(2-pyridin-2-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CC=N1 XGKZTUXQLQHHRV-LJQANCHMSA-N 0.000 description 1
- DEQYVHCCZTVYQX-HXUWFJFHSA-N 2-[(3r)-piperidin-3-yl]oxy-8-propan-2-yl-n-[(2-pyridin-3-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CN=C1 DEQYVHCCZTVYQX-HXUWFJFHSA-N 0.000 description 1
- WEIUXIOLAPFXMU-GOSISDBHSA-N 2-[(3r)-piperidin-3-yl]oxy-8-propan-2-yl-n-[(2-thiophen-2-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CS1 WEIUXIOLAPFXMU-GOSISDBHSA-N 0.000 description 1
- FEFHYHDGMCBDGI-QGZVFWFLSA-N 2-[(3r)-piperidin-3-yl]oxy-8-propan-2-yl-n-[[2-(1,2,4-triazol-1-yl)phenyl]methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=NC=N1 FEFHYHDGMCBDGI-QGZVFWFLSA-N 0.000 description 1
- JSFPMUJWLNMFKJ-UHFFFAOYSA-N 2-[[[2-(1,8-diazaspiro[4.5]decan-8-yl)-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-yl]amino]methyl]-n,n-dimethylbenzenesulfonamide Chemical compound N=1C(N2CCC3(NCCC3)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1S(=O)(=O)N(C)C JSFPMUJWLNMFKJ-UHFFFAOYSA-N 0.000 description 1
- BGSCDPUCDABDRV-UHFFFAOYSA-N 2-[[[2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-yl]amino]methyl]benzonitrile Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C#N BGSCDPUCDABDRV-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000006481 2-iodobenzyl group Chemical group [H]C1=C([H])C(I)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- ZLJKQOWJEZSNBE-UHFFFAOYSA-N 2-methylpropane-2-sulfinyl chloride Chemical compound CC(C)(C)S(Cl)=O ZLJKQOWJEZSNBE-UHFFFAOYSA-N 0.000 description 1
- BRUZQRBVNRKLJG-UHFFFAOYSA-N 2-methylpropyl carbamate Chemical compound CC(C)COC(N)=O BRUZQRBVNRKLJG-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- MXJSQBVMPQOFHN-GOSISDBHSA-N 2-n-[(3r)-piperidin-3-yl]-8-propan-2-yl-4-n-[(2-propan-2-yloxyphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine Chemical compound CC(C)OC1=CC=CC=C1CNC1=NC(N[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN12 MXJSQBVMPQOFHN-GOSISDBHSA-N 0.000 description 1
- JJFCHUHBTJUELP-QGZVFWFLSA-N 2-n-[(3r)-piperidin-3-yl]-8-propan-2-yl-4-n-[[2-(1,2,4-triazol-1-yl)phenyl]methyl]pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine Chemical compound N=1C(N[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=NC=N1 JJFCHUHBTJUELP-QGZVFWFLSA-N 0.000 description 1
- XVMRIGGUAJVFRW-UHFFFAOYSA-N 2-n-piperidin-3-yl-8-propan-2-yl-4-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine Chemical compound N=1C(NC2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 XVMRIGGUAJVFRW-UHFFFAOYSA-N 0.000 description 1
- JYBBMBQALCCSBF-UHFFFAOYSA-N 2-piperidin-4-yloxy-8-propan-2-yl-n-[(2-propan-2-yloxyphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CC(C)OC1=CC=CC=C1CNC1=NC(OC2CCNCC2)=NC2=C(C(C)C)C=NN12 JYBBMBQALCCSBF-UHFFFAOYSA-N 0.000 description 1
- IQRCUESBCAIQTF-UHFFFAOYSA-N 2-piperidin-4-yloxy-8-propan-2-yl-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 IQRCUESBCAIQTF-UHFFFAOYSA-N 0.000 description 1
- BHINGLXQFQEGND-UHFFFAOYSA-N 2-piperidin-4-yloxy-8-propan-2-yl-n-[(2-thiophen-2-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CS1 BHINGLXQFQEGND-UHFFFAOYSA-N 0.000 description 1
- YJAKHOGBXQOJQK-UHFFFAOYSA-N 2-piperidin-4-yloxy-8-propan-2-yl-n-[[2-(1,2,4-triazol-1-yl)phenyl]methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=NC=N1 YJAKHOGBXQOJQK-UHFFFAOYSA-N 0.000 description 1
- XTHPOQNWYUYMPZ-UHFFFAOYSA-N 2-piperidin-4-ylsulfinyl-8-propan-2-yl-n-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(S(=O)C2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CC=N1 XTHPOQNWYUYMPZ-UHFFFAOYSA-N 0.000 description 1
- JHFQXGBHFQBIEW-UHFFFAOYSA-N 2-piperidin-4-ylsulfinyl-8-propan-2-yl-n-[(2-thiophen-2-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(S(=O)C2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CS1 JHFQXGBHFQBIEW-UHFFFAOYSA-N 0.000 description 1
- YSMQHRDOXYUASZ-UHFFFAOYSA-N 2-piperidin-4-ylsulfinyl-8-propan-2-yl-n-[[2-(1,2,4-triazol-1-yl)phenyl]methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(S(=O)C2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=NC=N1 YSMQHRDOXYUASZ-UHFFFAOYSA-N 0.000 description 1
- WCMSFBRREKZZFL-UHFFFAOYSA-N 3-cyclohexen-1-yl-Benzene Chemical compound C1CCCC(C=2C=CC=CC=2)=C1 WCMSFBRREKZZFL-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- IHERZVGWOOXGGV-UHFFFAOYSA-N 4-aminopiperidine-1-carbaldehyde Chemical compound NC1CCN(C=O)CC1 IHERZVGWOOXGGV-UHFFFAOYSA-N 0.000 description 1
- SFRVHQSNMYFWPH-JKSUJKDBSA-N 4-n-[(1s)-1-(2-methoxyphenyl)ethyl]-2-n-[(3r)-piperidin-3-yl]-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine Chemical compound COC1=CC=CC=C1[C@H](C)NC1=NC(N[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN12 SFRVHQSNMYFWPH-JKSUJKDBSA-N 0.000 description 1
- CWZWNXZWMYEYTN-QGZVFWFLSA-N 8-propan-2-yl-2-[(3r)-pyrrolidin-3-yl]oxy-n-[(2-thiophen-2-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CS1 CWZWNXZWMYEYTN-QGZVFWFLSA-N 0.000 description 1
- CVXFLPQSKYIVCC-MRXNPFEDSA-N 8-propan-2-yl-2-[(3r)-pyrrolidin-3-yl]oxy-n-[[2-(1,2,4-triazol-1-yl)phenyl]methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=NC=N1 CVXFLPQSKYIVCC-MRXNPFEDSA-N 0.000 description 1
- RPKHPFZIFGBGIF-QGZVFWFLSA-N 8-propan-2-yl-n-[(2-propan-2-yloxyphenyl)methyl]-2-[(3r)-pyrrolidin-3-yl]oxypyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CC(C)OC1=CC=CC=C1CNC1=NC(O[C@H]2CNCC2)=NC2=C(C(C)C)C=NN12 RPKHPFZIFGBGIF-QGZVFWFLSA-N 0.000 description 1
- RRBRQNALHKQCAI-UHFFFAOYSA-N Acetildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1C(=O)CN1CCN(CC)CC1 RRBRQNALHKQCAI-UHFFFAOYSA-N 0.000 description 1
- CGVFRZMQURRQIE-UHFFFAOYSA-N COC1=CC=C(CN(C(CC=2SC=CC=2)=O)C2=CC(=C(C(=C2)OC)OC)OC)C=C1 Chemical compound COC1=CC=C(CN(C(CC=2SC=CC=2)=O)C2=CC(=C(C(=C2)OC)OC)OC)C=C1 CGVFRZMQURRQIE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101100156281 Drosophila melanogaster viaf gene Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- XVIXEGODDIOTBS-UHFFFAOYSA-N O=C1NCC11CNC1 Chemical compound O=C1NCC11CNC1 XVIXEGODDIOTBS-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BBKCOQYMKGEAAJ-UHFFFAOYSA-M [Br-].[Zn+]C1CCC1 Chemical compound [Br-].[Zn+]C1CCC1 BBKCOQYMKGEAAJ-UHFFFAOYSA-M 0.000 description 1
- VEIYYVKIXWXXLM-UHFFFAOYSA-N ac1mx1ji Chemical compound C1OC(C)(C)CC(C=2C3=NC=N4)=C1C(N1CCCC1)=NC=2SC3=C4NCCCN1CCOCC1 VEIYYVKIXWXXLM-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- WUVKNIDISMMQMO-UHFFFAOYSA-N ethyl n-(azetidin-3-yl)carbamate Chemical compound CCOC(=O)NC1CNC1 WUVKNIDISMMQMO-UHFFFAOYSA-N 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- YUPKNRGPZOEEQC-OAHLLOKOSA-N n-(1h-indazol-4-ylmethyl)-2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C2=C(C(C)C)C=NN2C(NCC=2C=3C=NNC=3C=CC=2)=NC=1O[C@@H]1CCCNC1 YUPKNRGPZOEEQC-OAHLLOKOSA-N 0.000 description 1
- SSMHMJPYAFYFKP-JKSUJKDBSA-N n-[(1s)-1-(2-methoxyphenyl)ethyl]-2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound COC1=CC=CC=C1[C@H](C)NC1=NC(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN12 SSMHMJPYAFYFKP-JKSUJKDBSA-N 0.000 description 1
- ZCRRPYAFOVZTHM-HNNXBMFYSA-N n-[(1s)-1-(2-methoxyphenyl)ethyl]-2-piperidin-4-yloxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound COC1=CC=CC=C1[C@H](C)NC1=NC(OC2CCNCC2)=NC2=C(C(C)C)C=NN12 ZCRRPYAFOVZTHM-HNNXBMFYSA-N 0.000 description 1
- HCUQGMNYTNWVDS-LSDHHAIUSA-N n-[(1s)-1-(2-methoxyphenyl)ethyl]-8-propan-2-yl-2-[(3r)-pyrrolidin-3-yl]oxypyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound COC1=CC=CC=C1[C@H](C)NC1=NC(O[C@H]2CNCC2)=NC2=C(C(C)C)C=NN12 HCUQGMNYTNWVDS-LSDHHAIUSA-N 0.000 description 1
- WFRXPKAFBONHQE-UHFFFAOYSA-N n-[(2,6-dichlorophenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=C(Cl)C=CC=C1Cl WFRXPKAFBONHQE-UHFFFAOYSA-N 0.000 description 1
- XIMJFCCFHLCOSI-UHFFFAOYSA-N n-[(2,6-difluorophenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=C(F)C=CC=C1F XIMJFCCFHLCOSI-UHFFFAOYSA-N 0.000 description 1
- RBDDVUAZTNMJBB-UHFFFAOYSA-N n-[(2-chloro-6-methylphenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=C(C)C=CC=C1Cl RBDDVUAZTNMJBB-UHFFFAOYSA-N 0.000 description 1
- PRTPWOFEDAPVID-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1Cl PRTPWOFEDAPVID-UHFFFAOYSA-N 0.000 description 1
- HPUBMJUATAJDKQ-UHFFFAOYSA-N n-[(2-ethoxyphenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CCOC1=CC=CC=C1CNC1=NC(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN12 HPUBMJUATAJDKQ-UHFFFAOYSA-N 0.000 description 1
- IVMCXYQHRPZVPU-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1F IVMCXYQHRPZVPU-UHFFFAOYSA-N 0.000 description 1
- AMFROXUQJQGDJE-UHFFFAOYSA-N n-[(2-imidazol-1-ylphenyl)methyl]-2-piperidin-4-yloxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N1C=CN=C1 AMFROXUQJQGDJE-UHFFFAOYSA-N 0.000 description 1
- NMHXXTFKBLPSKV-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound COC1=CC=CC=C1CNC1=NC(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN12 NMHXXTFKBLPSKV-UHFFFAOYSA-N 0.000 description 1
- OLJMORRXFYTEII-UHFFFAOYSA-N n-[(2-methylphenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C OLJMORRXFYTEII-UHFFFAOYSA-N 0.000 description 1
- GRXJVFVPTSRDHT-LJQANCHMSA-N n-[(2-morpholin-4-ylsulfonylphenyl)methyl]-2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1S(=O)(=O)N1CCOCC1 GRXJVFVPTSRDHT-LJQANCHMSA-N 0.000 description 1
- QLPROUWXYHWRAD-OAQYLSRUSA-N n-[(2-phenoxyphenyl)methyl]-2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1OC1=CC=CC=C1 QLPROUWXYHWRAD-OAQYLSRUSA-N 0.000 description 1
- KKFJANRGAVVEQV-UHFFFAOYSA-N n-[(2-phenylphenyl)methyl]-2-piperidin-4-yloxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CC=C1 KKFJANRGAVVEQV-UHFFFAOYSA-N 0.000 description 1
- FXSRTGLUWFVDKV-UHFFFAOYSA-N n-[(2-phenylphenyl)methyl]-2-piperidin-4-ylsulfinyl-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(S(=O)C2CCNCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CC=C1 FXSRTGLUWFVDKV-UHFFFAOYSA-N 0.000 description 1
- YEYXCGPUBXFUCT-QGZVFWFLSA-N n-[2-[[[2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-yl]amino]methyl]phenyl]acetamide Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1NC(C)=O YEYXCGPUBXFUCT-QGZVFWFLSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- HWLYEHPHZFMIRK-QGZVFWFLSA-N n-[[2-(1,3-oxazol-2-yl)phenyl]methyl]-2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=NC=CO1 HWLYEHPHZFMIRK-QGZVFWFLSA-N 0.000 description 1
- JYPAWUMVEPMZMD-UHFFFAOYSA-N n-[[2-(dimethylamino)phenyl]methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(OC2CCN(C)CC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1N(C)C JYPAWUMVEPMZMD-UHFFFAOYSA-N 0.000 description 1
- NMVSENCLIQTKGM-GOSISDBHSA-N n-[[2-(furan-2-yl)phenyl]methyl]-2-[(3r)-piperidin-3-yl]oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound N=1C(O[C@H]2CNCCC2)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1C1=CC=CO1 NMVSENCLIQTKGM-GOSISDBHSA-N 0.000 description 1
- ZRDWJCCYBHHVRB-UHFFFAOYSA-N phenyl 2-methylpropane-2-sulfinate Chemical compound CC(C)(C)S(=O)OC1=CC=CC=C1 ZRDWJCCYBHHVRB-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
Abstract
El compuesto de la fórmula general (I)**Fórmula** donde R1 representa a -H o a -CH3; R2 representa a -R8, -Q-R8, -R9, -Q-(CH2)n-R9, -(CH2)n-R9, -(CH2)n-NH-R8, -(CH2)m-NH-(CH2)n-R9, -CO- **Fórmula** R3 representa a **Fórmula** ii) C1-C8-alquilo lineal o ramificado, C3-C8-cicloalquilo, C1-C9-heterociclilo, C2-C8-alquenilo lineal o ramificado, C2-C8-alquinilo lineal o ramificado, C6-C14-arilo, C1-C10-heteroarilo, donde los residuos ya mencionados pueden ser sustituidos con 1 a 5 sustituyente seleccionados de Z8, Z9, Z10, Z11 y Z12; iii) heterociclilos de 3 miembros, heterociclilos de 4 miembros, heterociclilos de 5 miembros, heterociclilos de 6 miembros, heterociclilos monoinsaturados de 4 miembros, heterociclilos monoinsaturados de 5 miembros, heterociclilos monoinsaturados de 6 miembros, carbociclilos de 3 miembros, carbociclilos de 4 miembros, carbociclilos de 5 miembros, carbociclilos de 6 miembros, arilos de 6 miembros, heteroarilos de 5 55 miembros, heteroarilos de 6 miembros, donde todos los sistemas anulares ya mencionados pueden ser sustituidos con 1 a 4 sustituyente seleccionados de Z1, Z2, Z3 y Z4; Z1 y Z2 si estuviesen adheridos al mismo átomo carbono juntos puede representar a >=O para formar a un grupo carbonilo con el átomo carbono al cual Z1 y Z2 están adheridos; R3 junto con R4 pueden formar a un anillo carbocíclico o heterocíclico de 4, 5, 6 o 7 miembros con los 2 átomos carbonos del anillo benzo al cual R3 y R4 están adheridos y aquel anillo de 4, 5, 6 o 7 miembros puede ser parcialmente saturado o insaturado y puede ser sustituido con 1 a 4 sustituyente seleccionados de Z1, Z2, Z3 y Z4; Z1 y Z2 si estuviesen adheridos al mismo átomo carbono pueden representar en conjunto a >=O para formar un grupo carbonilo con el átomo carbono al cual Z1 y Z2 están adheridos; R4-R7 representan independientemente entre sí a -H, -F, -Cl, -CH3; R8 representa a -(CH2)p-NH2, -(CH2)p-N(R16R17), carbociclilos, heterociclilos, espirocarbociclilos, espiroheterociclilos, donde los residuos carbociclilos, heterociclilos, espirocarbociclilos y espiroheterociclilos ya mencionados están enlazados a través de un átomo carbono anular y pueden ser sustituidos con 1 a 3 sustituyente seleccionados de Z5, Z6 y Z7; Z5 y Z6 si estuviesen adheridos al mismo átomo carbono pueden representar en conjunto a >=O para formar un grupo carbonilo con el átomo carbono al cual Z5 y Z6 están adheridos; R9 representa a -R8, nitrogenoheterociclilo, espironitrogenociclilo, donde los residuos nitrogenosheterociclilos y espironitrogenoheterociclilos ya mencionados están enlazados a través de un átomo nitrógeno y puede ser sustituidos con 1 a 3 sustituyente seleccionados de Z5, Z6 y Z7; Z5 y Z6 si estuviesen adheridos al mismo átomo carbono en conjunto pueden representar a >=O para formar un grupo carbonilo con el átomo carbono al cual Z5 y Z6 están adheridos; R11, R12 R13, R14 y R15 representan independientemente entre sí a -H, C1-C8-alquilo lineal o ramificado, C3-C8- cicloalquilo, C1-C9-heterociclilo, C2-C8-alquenilo lineal o ramificado, C2-C8-alquinilo lineal o ramificado, C6-C14-arilo, C1-C10-heteroarilo, Donde los residuos ya mencionados pueden ser sustituidos con 1 a 5 sustituyente seleccionados de Z8, Z9, Z10, Z11 y Z12; R11 junto con R12 pueden formar a un anillo carbocíclico o heterocíclico de 4, 5 o 6 miembros y aquel anillo de 4, 5 o 6 miembros puede ser saturado o insaturado y puede ser sustituido con 1 a 8 sustituyentes seleccionados de Z8, Z9, Z10, Z11, Z12, Z13, Z14 y Z15; Z8 y Z9 si estuviesen adheridos al mismo átomo carbono juntos podrían representar a >=O para formar un grupo carbonilo con el átomo carbono al cual Z8 y Z9 están adheridos; R10, R16 y R17 representan independientemente entre sí a -H, -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2F, -CHF2, -CF3,**Fórmula**
Description
Donde residuos pueden ser sustituidos con 1 a 5 sustituyentes seleccionados de Z8, Z9, Z10, Z11 y Z12. Sin embargo, es claro para una persona con conocimiento en la industria que el término “pueden ser sustituidos” se refiere al reemplazo de un átomo hidrógeno por uno de los sustituyentes Z8, Z9, Z10, Z11 o Z12. Además, es claro para una persona con conocimiento en que únicamente que estos átomos hidrógenos que están presentes en el residuo pueden ser reemplazados por los sustituyentes Z8, Z9, Z10, Z11 y Z12. Por lo tanto, puesto que el grupo vinilo tiene únicamente 3 átomos hidrógenos, únicamente 3 átomos hidrógeno pueden ser reemplazados por 3 sustituyentes seleccionados de Z8, Z9, Z10, Z11 y Z12. El número de átomos carbonos C2-C8 se refiere únicamente a los átomos
Z12
carbonos del residuo alquenilo y no incluye a los átomos carbonos de los sustituyentes Z8 a . Para las definiciones utilizadas en este documento, el grupo -CH=CH-Ph debería clasificarse bajo el término “C 2-C8-alquenilo lineal o ramificado” [0052] Se prefieren a -CH=CH2, -CH2-CH=CH2, -C(CH3)=CH2, -CH=CH-CH3, -C2H4-CH=CH2, -CH2-CH=CH-CH3. Se prefieren especialmente a -CH=CH2, -CH2-CH=CH2, y -CH=CH-CH3.
[0054] Tal como se utiliza en este documento, el término “C2-C8-alquinilo lineal o ramificado” se refiere a -C≡CH, C≡C-CH3, -CH2-C≡CH,
-C≡C-Ph, -C2H4-CH(CH3)-C≡C-C≡CH, -C2H4-CH(C≡CH)-CH2-C≡CH, -C2H4-C(C≡CH)2-CH3, -C3H6-CH(C≡CH)2, -C2H4-CH(C≡CH)-C≡C-CH3, donde estos residuos pueden ser sustituidos con 1 a 5 sustituyente seleccionados de Z8, Z9, Z10, Z11 y Z12. Sin embargo, es claro para una persona con conocimiento en la industria que el término “pueden ser sustituidos” se refiere al reemplazo de un átomo hidrógeno por uno de los sustituyentes Z8, Z9, Z10, Z11 o Z12. Además, es claro para una persona con conocimiento en la industria que únicamente estos átomos hidrógenos que están presentes en el residuo pueden ser reemplazados por los sustituyentes Z8, Z9, Z10, Z11 y Z12. Por lo tanto, puesto que el grupo acetilenilo sólo tiene un átomo hidrógeno, únicamente en un átomo hidrógeno puede ser reemplazado por un sustituyente seleccionado de Z8, Z9, Z10, Z11 y Z12. El número de átomos carbonos de C2-C8 se refiere únicamente a los átomos carbonos del residuo alquinilo y no incluye a los átomos carbonos de los
18
ciclo-C3H5, ciclo-C4H7, ciclo-C5H9, ciclo-C6H11, ciclo-C7H13, -C4H9, -CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3,
-C2H4-OC2H5, -C3H6-OC2H5.
[0140] En un aspecto adicional de este invento, los compuestos nuevos de acuerdo a la fórmula general (I) representan a compuestos quirales. Los compuestos nuevos de acuerdo a la fórmula general (I) representan a un racemato, o a un S o un enantiómero R o a una mezcla de isómeros. [0141] En otra sección preferida de este invento, el compuesto de acuerdo a la fórmula general (I) es seleccionado de un grupo de compuestos descritos en la siguiente tabla 1.
Tabla 1:
- compuesto
- nombre
- (VII-01)
- N-(2-(1 H-pirazol-1-il)benzil)-8-isopropil-2-(piperidin-4-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-02)
- (R)-N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(pirrolidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-03)
- (R)-N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(piperidin-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-04)
- N-(2-(1 H-pirazol-1-il)benzil)-2-(2-azaspiro[3.3]heptano-6-iloxi)-8-isopropylpirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-05)
- 2-(1-oxa-8-azaspiro[4.5]decano-3-iloxi)-N-(2-(1 H-pirazol-1-il)benzil)-8-isopropylpirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-06)
- N-(1-(2-(1 H-pirazol-1-il)fenil)etil)-8-isopropil-2-((R)-piperidin-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-07)
- (R)-N-([1,1’-bifenil]-2-ilmetil)-8-isopropil-2-(piperidin-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-08)
- (R)-N-([1,1’-bifenil]-2-ilmetil)-8-isopropil-2-(pirrolidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-09)
- N-([1,1’-bifenil]-2-ilmetil)-8-isopropil-2-(piperidin-4-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-10)
- 8-isopropil-N-((S)-1-(2-metoxifenil)etil)-2-((R)-piperidin-3-iloxi)pirazolo[1,5-a][1,3,5]triazina4-amina
- (VII-11)
- 8-isopropil-N-((S)-1-(2-metoxifenil)etil)-2-((R)-pirrolidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina4-amina
- (VII-12)
- (R)-8-isopropil-2-(piperidina-3-iloxi)-N-(2-(tiofen-2-il)benzil)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-13)
- (R)-8-isopropil-2-(pirrolidina-3-iloxi)-N-(2-(tiofen-2-il)benzil)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-14)
- 8-isopropil-2-(piperidina-4-iloxi)-N-(2-(tiofen-2-il)benzil)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-15)
- (S)-8-isopropil-N-(1-(2-metoxifenil)etil)-2-(piperidina-4-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-16)
- (R)-N-(2-isopropoxibenzil)-8-isopropil-2-(pirrolidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-17)
- N-(2-isopropoxibenzil)-8-isopropil-2-(piperidina-4-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-18)
- (R)-N-(2-isopropoxibenzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-19)
- N-(2-(1 H-imidazol-1-il)benzil)-8-isopropil-2-(piperidina-4-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-20)
- (R)-N-(2-(1H-1,2,4-triazol-1-il)benzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina4-amina
- (VII-21)
- (R)-N-(2-(1 H-1,2,4-triazol-1-il)benzil)-8-isopropil-2-(pirrolidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina4-amina
- (VII-22)
- N-(2-(1 H-1,2,4-triazol-1-il)benzil)-8-isopropil-2-(piperidina-4-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-23)
- (R)-8-isopropil-N-(2-(2-metil-1H-imidazol-1-il)benzil)-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-24)
- 8-isopropil-N-(2-(2-metil-1 H-imidazol-1-il)benzil)-2-(piperidina-4-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-25)
- (R)-8-isopropil-N-(2-(2-metil-1H-imidazol-1-il)benzil)-2-(pirrolidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-26)
- (R)-N-(2-(1H-imidazol-1-il)benzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII 30)
- 1
86
Continua
- (VII-27)
- (R)-N-(2-(1H-imidazol-1-il)benzil)-8-isopropil-2-(pirrolidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-28)
- N-((S)-1-(2-chlorofenil)etil)-8-isopropil-2-((R)-piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-29)
- (R)-8-isopropil-N-(2-(1-metil-1H-tetrazol-5-il)benzil)-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-30)
- 11-óxido de (R)-5-(((8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)quinolina
- (VII-31)
- (R)-8-isopropil-N-(isoquinolin-8-ilmetil)-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-32)
- 2-óxido de (R)-8-(((8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)isoquinolina
- (VII-33)
- (R)-8-isopropil-N-((1-metil-1H-indazol-4-il)metil)-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-34)
- (R)-8-isopropil-2-(piperidina-3-iloxi)-N-(2-(pyridin-2-il)benzil)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-35)
- (R)-8-isopropil-2-(piperidina-3-iloxi)-N-(quinolin-8-ilmetil)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-36)
- (R)-N-((1H-indazol-4-il)metil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-37)
- (R)-8-isopropil-N-(2-(2-metil-2H-tetrazol-5-il)benzil)-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-38)
- (R)-2-(((8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-il)amino)metil)N,Ndimethilbenzenesulfonamida
- (VII-39)
- (R)-1-(2-(((8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)fenil)pirrolidina-2-ona
- (VII-40)
- (R)-1-(2-(((8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)fenil)azetidina-2-ona
- (VII-41)
- (R)-N-(5-fluoro-2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-42)
- (R)-N-(3-fluoro-2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-43)
- (R)-N-(4-fluoro-2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-44)
- (R)-N-(2-fluoro-6-(1H-pirazol-1-il)benzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-45)
- 8-isopropil-2-((1-metilpiperidina-4-il)oxi)-N-(2-(piridina-3-il)benzil)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-46)
- (R)-8-isopropil-2-(piperidina-3-iloxi)-N-(2-(piridina-3-il)benzil)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-47)
- 8-isopropil-2-((1-metilpiperidina-4-il)oxi)-N-(2-fenoxibenzil)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-48)
- (R)-8-isopropil-N-(2-fenoxibenzil)-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-49)
- (R)-8-isopropil-N-(2-(oxazol-2-il)benzil)-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-50)
- (R)-N-(2-(furano-2-il)benzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-51)
- (R)-N-(2-(((8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)fenil)acetamida
- (VII-52)
- R)-N-(2-(4-cloro-1 H-pirazol-1-il)benzil)-8-isopropil-2-(piperidina-3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-53)
- 8-isopropil-N-(2-metilbenzil)-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-54)
- N-(2-(dimetilamino)benzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina4-amina
- (VII-55)
- 2-(((8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)benzonitrilo
- (VII-56)
- N-(2-fluorobenzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-57)
- N-([1,1’-bifenil]-2-ilmetil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-58)
- 8-isopropil-2-((1-metilpiperidina-4-il)oxi)-N-(2-(trifluorometil)benzil)pirazolo[1,5-a][1,3,5]triazina4-amina
- (VII-59)
- N-(2-(1 H-imidazol-1-il)benzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-60)
- 8-isopropil-2-((1-metilpiperidina-4-il)oxi)-N-(2-morfolinobenzil)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-61)
- 8-isopropil-2-((1-metilpiperidina-4-il)oxi)-N-(nafthalen-1-ilmetil)pirazolo[1,5-a][1,3,5]triazina-4amina
87
continua
- (VII-62)
- N-(2-cloro-6-metilbenzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina4-amina
- (VII-63)
- N-(2,6-diclorobenzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-64)
- N-(2,6-difluorobenzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-65)
- 8-isopropil-2-((1-metilpiperidina-4-il)oxi)-N-(2-(tiofen-2-il)benzil)pirazolo[1,5-a][1,3,5]triazina4-amina
- (VII-66)
- N-(2-isopropoxibenzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-67)
- (S)-8-isopropil-N-(1-(2-metoxifenil)etil)-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-68)
- N-(2-clorobenzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-69)
- (S)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)-N-(1-(naftalen-1-il)etil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-70)
- N-(2-etoxibenzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-71)
- 8-isopropil-N-(2-metoxibenzil)-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5-a][1,3,5]triazina-4amina
- (VII-72)
- N-(2-(difluorometoxi)benzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-73)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-74)
- N-(2-(1 H-1,2,4-triazol-1-il)benzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-75)
- 8-isopropil-N-(2-(2-metil-1H-imidazol-1-il)benzil)-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-76)
- N-(2-(difluorometoxi)benzil)-8-isopropil-2-((1-metilpiperidina-4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-77)
- 2-(((2-(2-(dimetilamino)etoxi)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)benzoato de metilo
- (VII-78)
- 2-((6-aminoespiro[3.3]heptano-2-il)oxi)-8-isopropil-N-(quinolin-5-ilmetil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-79)
- 8-isopropil-2-(2-(piperidina-4-il)etoxi)-N-(quinolin-5-ilmetil)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-80)
- N-(2-aminobenzil)-2-(azetidin-3-ilmetoxi)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-4-amina
- (VII-89)
- (2-(((8-isopropil-2-(2-(piperidina-1-il)etoxi)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)fenil)carbamato de terc-butilo
- (VII-90)
- N-(2-(((2-(2-(2-(dimetilamino)etoxi)etoxi)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)fenil)metanosulfonamida
- (VII-91)
- N-(2-(((2-(2-((2-(dimetilamino)etil)(metil)amino)etoxi)-8-isopropilpirazolo[1,5a][1,3,5]triazina-4-il)amino)metil)fenil)metanosulfonamida
- (VIII-01)
- N4-(2-(1H-pirazol-1-il)benzil)-8-isopropil-N2-(piperidina-3-il)pirazolo[1,5-a][1,3,5]triazina-2,4diamina
- (VIII-02)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,6-diazaespiro[3.4]octan-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-03)
- N-(2-(1 H-pirazol-1-il)benzil)-8-isopropil-2-(2,7-diazaespiro[4.4]nonan-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-04)
- N-(2-(1 H-pirazol-1-il)benzil)-8-isopropil-2-(1,6-diazaespiro[3.5]nonano-1-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-05)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,6-diazaespiro[3.5]nonano-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-06)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,6-diazaespiro[4.5]decaon-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-07)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,6-diazaespiro[3.4]octano-6-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-08)
- N-(2-(1 H-pirazol-1-il)benzil)-8-isopropil-2-(1,6-diazaespiro[3.3]heptano-1-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-09)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,8-diazaespiro[4.5]decaon-8-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-10)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,6-diazaespiro[3.3]heptano-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-11)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,8-diazaespiro[4.5]decano-8-il)pirazolo[1,5
88
Continua
- (VIII-12)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,7-diazaespiro[3.5]nonano-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-13)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,7-diazaespiro[4.4]nonano-1-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-14)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,8-diazaespiro[5.5]undecano-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-15)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,8-diazaespiro[5.5]undecano-8-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-16)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,7-diazaespiro[3.5]nonano-7-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-17)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,7-diazaespiro[4.4]nonano-7-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-18)
- 8-isopropil-N-(2-(1-metil-1H-tetrazol-5-il)benzil)-2-(1,8-diazaespiro[4.5]decano-8-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-19)
- 8-isopropil-N-(2-(2-metil-2H-tetrazol-5-il)benzil)-2-(1,8-diazaespiro[4.5]decano-8-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-20)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,7-diazaespiro[3.5]nonano-7-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-21)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,9-diazaespiro[5.5]undecano-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-22)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,8-diazaespiro[4.5]decano-1-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-23)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,9-diazaespiro[5.5]undecano-9-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-24)
- N-(2-(1H-pirazol-1-il)benzil)-2-(4-(dimetilamino)piperidina-1-il)-8-isopropilpirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-25)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(4-(metilamino)piperidina-1-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-26)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(3,9-diazaespiro[5.5]undecano-3-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-27)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,7-diazaespiro[4.5]decano-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-28)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,6-diazaespiro[3.4]octano-1-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-31)
- 8-isopropil-N4-((S)-1-(2-metoxifenil)etil)-N2-((R)-piperidina-3-il)pirazolo[1,5-a][1,3,5]triazina2,4-diamina
- (VIII-32)
- (R)-N4-(2-isopropoxibenzil)-8-isopropil-N2-(piperidina-3-il)pirazolo[1,5-a][1,3,5]triazina-2,4diamina
- (VIII-33)
- (R)-N4-(2-(1H-1,2,4-triazol-1-il)benzil)-8-isopropil-N2-(piperidina-3-il)pirazolo[1,5-a][1,3,5]triazina2,4-diamina
- (VIII-34)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(1,7-diazaespiro[3.5]nonano-1-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-35)
- 2-(((8-isopropil-2-(1,8-diazaespiro[4.5]decano-8-il)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)-N,N-dimetilbenzenosulfonamida
- (VIII-36)
- N-(benzo[c][1,2,5]oxadiazol-4-ilmetil)-8-isopropil-2-(1,8-diazaespiro[4.5]decano-8-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-37)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(2,8-diazaespiro[4.5]decano-2-il)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-38)
- 1-(2-(((8-isopropil-2-(1,8-diazaespiro[4.5]decano-8-il)pirazolo[1,5-a][1,3,5]triazina-4il)amino)metil)fenil)pirrolidina-2-ona
- (X-1)
- N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(piperidina-4-ilsulfinil)pirazolo[1,5-a][1,3,5]triazina-4amina
- (X-2)
- 8-isopropil-2-(piperidina-4-ilsulfinil)-N-(2-(tiofen-2-il)benzil)pirazolo[1,5-a][1,3,5]triazina-4-amina
- (X-3)
- N-([1,1’-bifenil]-2-ilmetil)-8-isopropil-2-(piperidina-4-ilsulfinil)pirazolo[1,5-a][1,3,5]triazina-4amina
- (X-4)
- N-(2-(1H-1,2,4-triazol-1-il)benzil)-8-isopropil-2-(piperidina-4-ilsulfinil)pirazolo[1,5-a][1,3,5]triazina4-amina
- (X-5)
- 8-isopropil-N-(2-(2-metil-1H-imidazol-1-il)benzil)-2-(piperidina-4-ilsulfinil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (XII-1)
- 4-((2-(1H-pirazol-1-il)benzil)amino)-8-isopropil-N-(piperidina-4-ilmetil)pirazolo[1,5a][1,3,5]triazina-2-carboxamida
89
- Compues to
- Fórmula Calcula do MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VII-01)
- C23H28N8O 432.24 433.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(piperidina-4iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-02)
-
C22H26N8O
418.22
418.9
(VI-a)
(R)-N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(pirrolidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
imagen133
- (VII-03)
- C23H28N8O 432.24 433.3 (VI-a) (R)-N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-04)
-
C24H28N8O
444.24
445.7
(VI-a)
N-(2-(1H-pirazol-1il)benzil)-2-(2azaespiro[3.3]heptano6-iloxi)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
imagen134
- (VII-05)
- C26H32N8O2 488.26 489.4 (VI-a) 2-(1-oxa-8azaspiro[4.5]decano-3iloxi)-N-(2-(1H-pirazol1-il)benzil)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
- (VII-06)
- C24H3ON8O 446.25 447.4 (VI-a) N-(1-(2-(1H-pirazol-1
- il)fenil)etil)-8-isopropil
- 2-((R)-piperidina-3
- iloxi)pirazolo[1,5
- ][1,3,5]triazina
- 4-amina
- (VII-07)
- C26H3ON6O 442.25 443.5 (VI-b) (R)-N-([1,1’-bifenil]-2ilmetil)-8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
136 Continua
- Compuesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VII-08)
- C25H28N6O 428.23 429.2 (VI-b) (R)-N-([1,1’-bifenil]-2ilmetil)-8-isopropil2-(pirrolidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-09)
- C26H3ON6O 442.25 443.3 (VI-b) N-([1,1’-bifenil]-2ilmetil)-8-isopropil2-(piperidina-4iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-10)
- C22H3ON6O2 410.24 411.4 (VI-c) 8-isopropil-N-((S)-1
- (2-metoxifenil)etil)
- 2-((R)-piperidin-3
- iloxi)pirazolo[1,5
- a][1,3,5]triazina
- 4-amina
- (VII-11)
- C21H28N6O2 396.23 397.4 (VI-c) 8-isopropil-N-((S)-1(2-metoxifenil)etil)2-((R)-pirrolidin-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-12)
- C24H28N6OS 448.20 449.3 (VI-d) (R)-8-isopropil-2(piperidin-3-iloxi)-N(2-(tiofen2il)benzil)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-13)
- C23H26N6OS 434.19 435.3 (VI-d) (R)-8-isopropil-2(pirrolidina-3iloxi)-N-(2-(tiofen-2il)benzil)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-14)
-
C24H28N6OS
448.20
449.1
(VI-d)
8-isopropil-2(piperidin-4-iloxi)-N(2-(tiofen-2il)benzil)pirazolo[1,5a][1,3,5]triazina-4amina
imagen135
137 Continua
- Compuesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VII-15)
- C22H3ON6O2 411.3 (VI-c) (S)-8-isopropil-N(1-(2metoxifenil)etil)2-(piperidin-4iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-16)
- C22H3ON6O2 411.1 (VI-e) (R)-N-(2isopropoxibenzil)-8isopropil2-(pirrolidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-17)
- C23H32N6O2 424.26 425.4 (VI-e) N-(2isopropoxibenzil)-8isopropil-2(piperidina-4iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-18)
- C23H32N6O2 424.26 425.3 (VI-e) (R)-N-(2isopropoxibenzil)-8isopropil-2(piperidina3-iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-19)
- C23H28N8O 432.24 433.4 (VI-f) N-(2-(1H-imidazol1-il)benzil)-8isopropil2-(piperidina-4iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-20)
- C22H27N9O 433.23 434.3 (VI-g) (R)-N-(2-(1H-1,2,4triazol-1-il)benzil)-8isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-21)
- C21H25N9O 419.22 419.8 (VI-g) (R)-N-(2-(1H-1,2,4triazol-1-il)benzil)-8isopropil2-(pirrolidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
138 continua
- (VII22)
-
C22H27N9O
433.23
434.0
(VIg)
N-(2-(1H-1,2,4-triazol-1il)benzil)-8-isopropil2-(piperidina-4iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
imagen136
- (VII23)
- C24H3ON8O 446.25 447.2 (VIh) (R)-8-isopropil-N-(2-(2metil-1H-imidazol-1il)benzil)-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII24)
-
C24H30N8O
446.25
447.3
(VIh)
8-isopropil-N-(2-(2-metil1H-imidazol-1il)benzil)-2-(piperidina-4iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
imagen137
- (VII25)
- C23H28N8O*2C2HF 3O2 432.24 433.3 (VIh) (R)-8-isopropil-N-(2-(2metil-1H-imidazol-1il)benzil)-2-(pirrolidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII26)
- C23H28N8O 432.24 433.2 (VI-f) (R)-N-(2-(1H-imidazol-1il)benzil)-8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII27)
- C22H26N8O*2C2HF 3O2 418.22 419.3 (VI-f) (R)-N-(2-(1H-imidazol-1il)benzil)-8-isopropil2-(pirrolidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII28)
- C21H27ClN6O 414.19 415.4 (VI-i) N-((S)-1-(2-clorofenil)etil)-8-isopropil-2-((R)piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
139 continua
- (VII29)
- C22H28N10O 448.24 449.3 (VI-j) (R)-8-isopropil-N-(2-(1metil-1H-tetrazol-5il)benzil)-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII30)
- C23H27N7O2 433.22 434.1 (VIk) 1-óxido de (R)-5-(((8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)quinolina
- (VII31)
- C23H27N7O 417.23 418.3 (VI1) (R)-8-isopropil-N(isoquinolin-8-ilmetil)2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII32)
- C23H27N7O2 433.22 434.0 (VIm) 2-óxido de (R)-8-(((8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)isoquinolina
- (VII33)
- C22H28N8O 420.24 421.4 (VIn) (R)-8-isopropil-N-((1metil-1H-indazol-4il)metil)-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII34)
- C25H29N7O 443.24 444.4 (VIo) (R)-8-isopropil-2(piperidina-3-iloxi)-N-(2(pyridin-2il)benzil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII35)
- C23H27N7O 417.23 418.3 (VI-P) (R)-8-isopropil-2(piperidina-3-iloxi)-N(quinolina-8ilmetil)pirazolo[1,5a][1,3,5]triazina-4-amina
140 continua
- compuesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VII-36)
- C21H26N8O 406.22 407.3 (VI-r) (R)-N-((1H-indazol-4il) metil)-8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-37)
- C22H28N10O 448.24 449.5 (VI-t) (R)-8-isopropil-N-(2(2metil-2H-tetrazol5il)benzil)-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-38)
-
C22H31N7O3S
473.22
474.4
(VI-u)
Amida de (R)-2-(((8isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)-N,Ndimetilbenzenosulfon
imagen138
- (VII-39)
- C24H31N7O2 449.25 450.5 (VI-s) (R)-1-(2-(((8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil) pirrolidina-2-ona
- (VII-40)
- C23H29N7O2 435.238 273 436.4 (VI-v) (R)-1-(2-(((8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil )azetidin-2-ona
- (VII-41)
-
C23H27FN8O
450.23
451.5
(VI-w)
(R)-N-(5-fluoro-2-(1Hpirazol-1-il)benzil)-8isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
imagen139
141 continua
- (VII-42)
- C23H27FN8O 450.23 451.4 (VI-x) (R)-N-(3-fluoro-2-(1Hpirazol-1-il)benzil)-8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-43)
- C23H27FN8O 450.23 451.4 (VI-y) (R)-N-(4-fluoro-2-(1Hpirazol-1-il)benzil)-8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-44)
- C23H27FN8O 450.23 451.5 (VI-z) (R)-N-(2-fluoro-6-(1Hpirazol-1-il)benzil)-8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-45)
- C26H31N7O 457.26 458.3 (VIaa) 8-isopropil-2-((1metilpiperidina-4il)oxi)-N-(2-(piridina-3il)benzil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-46)
- C25H29N7O 443.24 444.3 (VIaa) (R)-8-isopropil-2(piperidina-3-iloxi)-N-(2(piridina-3il)benzil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-47)
- C27H32N6O2 472.26 472.9 (VIab) 8-isopropil-2-((1metilpiperidina-4-il)oxi)N-(2fenoxibenzil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-48)
- C26H30N6O2 458.24 459.0 (VIab) (R)-8-isopropil-N-(2fenoxibenzil)-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
142 continua
- (VII49)
- C23H27N7O2 433.22 434.7 (VIac) (R)-8-isopropil-N-(2-(oxazol2-il)benzil)2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII50)
- C24H28N6O2 432.23 433.6 (VIad) (R)-N-(2-(furan-2-il)benzil)-8isopropil-2-(piperidina3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII51)
- C22H29N7O2 423.24 424.3 (VIae) (R)-N-(2-(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenilI)acetamida
- (VII52)
- C23H27ClN8O 466.20 467.3 (VIaf) (R)-N-(2-(4-cloro-1H-pirazol1-il)benzil)-8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII53)
-
C22H30N6O
394.25
395.47
(XIX)
8-isopropil-N-(2-metilbenzil)2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
imagen140
- (VII54)
- C23H33N7O 423.27 424.46 (XIX) N-(2-(dimetilamino)benzil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII55)
- C22H27N7O 405.23 406.3 (XIX) 2-(((8-isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)benzonitrilo
143 continua
- (VII56)
- C21H27FN6O 398.22 399.4 (XIX) N-(2-fluorobenzil)-8-isopropil-2((1-metilpiperidina4-il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII57)
- C27H32N6O 456.26 457.09 (XIX) N-([1,1’-bifenil]-2-ilmetil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII58)
- C22H27F3N6O 448.22 449.18 (XIX) 8-isopropil-2-((1-metilpiperidina4il)oxi)-N-(2(trifluorometil)benzil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII59)
- C24H30N8O 446.25 447.49 (XIX) N-(2-(1H-imidazol-1-il)benzil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII60)
-
C25H35N7O2
465.29
466.36
(XIX)
8-isopropil-2-((1-metilpiperidina4-il)oxi)-N-(2morpholinobenzil)pirazolo[1,5a][1,3,5]triazina-4amina
imagen141
- (VII61)
- C25H30N6O 430.25 431.21 (XIX) 8-isopropil-2-((1-metilpiperidina4il)oxi)-N-(naftaleno-1ilmetil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII62)
- C22H29ClN6O 428.21 429.19 (XIX) N-(2-cloro-6-metilbenzil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
144 continua
- (VII63)
- C21H26Cl2N6O 448.15 449.14 (XIX) N-(2,6-diclorobenzil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII64)
- C21H26F2N6O 416.21 417.19 (XIX) N-(2,6-difluorobenzil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII65)
- C25H30N6OS 462.22 463.43 (XIX) 8-isopropil-2-((1metilpiperidina-4il)oxi)-N-(2-(tiofen-2il)benzil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII66)
- C24H34N6O2 438.27 439.09 (XIX) N-(2-isopropoxibenzil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII67)
- C23H32N6O2 424.26 425.25 (XIX) (S)-8-isopropil-N-(1-(2metoxifenil)etil)-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII68)
- C21H27ClN6O 414.19 415.35 (XIX) N-(2-clorobenzil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII69)
-
C26H32N6O
444.26
445.39
(XIX)
(S)-8-isopropil-2-((1metilpiperidina-4il)oxi)-N-(1-(naftaleno-1il)etil)pirazolo[1,5a][1,3,5]triazina-4-amina
imagen142
145 continua
- compuesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VII-70)
- C23H32N6O2 424.26 425.17 (XIX) N-(2-etoxibenzil)-8isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-71)
-
C22H30N6O2
410.24
411.07
(XIX)
8-isopropil-N-(2metoxibenzil)-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4amina
imagen143
- (VII-72)
- C22H28F2 N6O2 446.22 447.08 (XIX) N-(2(difluorometoxi)benzil)8-isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-73)
- C24H30N8O 446.25 447.00 (XIX) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-74)
- C23H29N9O 447.25 447.94 (XIX) N-(2-(1H-1,2,4-triazol1-il)benzil)-8-isopropil2-((1-metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-75)
- C25H32N8O* 460.27 461.35 (XIX) 8-isopropil-N-(2-(2
- 2C2HF
- metil-1H-imidazol-1
- 3O2
- il)benzil)-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII-76)
- C22H27F3N 6O2 464.21 464.97 (XIX) N-(2(difluorometoxi)benzil)8-isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4amina
146 continua
- (VII77)
- C21H28N6O3 412.22 413.6 (VIah) 2-(((2-(2-(dimetilamino)etoxi)8isopropilpirazolo[1,5-a][1,3,5] triazina-4il)amino)metil) benzoato de metilo
- (VII78)
- C25H29N7O 443.24 444.7 (VIaj) 2-((6-aminospiro[3.3]heptano-2-il)oxi)-8-isopropil-N(quinolina-5ilmetil)pirazolo[1,5-a][1,3,5] triazina4-amina
- (VII79)
- C25H31N7O 445.26 446.6 (VIaj) 8-isopropil-2-(2-(piperidina-4-il) etoxi)-N-(quinolina5-ilmetil)pirazolo[1,5-a][1,3,5] triazina-4-amina
- (VII80)
- C19H25N7O 367.21 368.5 (VIaj) N-(2-aminobenzil)-2-(azetidin3-ilmetoxi)-8isopropilpirazolo[1,5-a][1,3,5] triazina-4-amina
- (VII89)
- C27H39N7O3 509.31 510.7 (VIaj) (2-(((8-isopropil-2-(2(piperidina-1il)etoxi)pirazolo[1,5-a][1,3,5] triazina4il)amino)metil)fenil)carbamato de terc-butilo
- (VII90)
- C22H33N7O4S 491.23 492.6 (VIag) N-(2-(((2-(2-(2(dimetilamino)etoxi)etoxi)-8isopropilpirazolo[1,5-a][1,3,5] triazina-4il)amino)metil)fenil) metanosulfonamida
- (VII91)
- C23H36N8O3S 504.26 505.5 (VIag) N-(2-(((2-(2-((2(dimetilamino)etil)(metil)amino) etoxi)-8isopropilpirazolo[1,5a][1,3,5] triazina-4il)amino)metil)fenil) metanosulfonamida
147 continua
- (VII92)
- C25H33N7O2 463.27 464.4 (VIaI) (R)-1-(2-(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)benzil)pirrolidina2-ona
- (VII93)
- C25H34N6O3 466.27 467.4 (VIam) 8-isopropil-N-(4-metil-2((tetrahidrofurano-3il)oxi)benzil)-2-((R)-piperidina3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII94)
- C20H24Cl2N6O 434.14 435.3 (VIak) (R)-N-(2,4-diclorobenzil)-8isopropil-2-(piperidina3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII95)
- C25H34N6O2 450.27 451.4 (VIan) (R)-N-(2-(ciclopentiloxi)benzil)8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII96)
- C21H27N7O2 409.22 410.4 (VIao) (R)-2-(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)benzamida
- (VII97)
- C24H32N6O2 436.26 437.4 (VIap) (R)-N-(2-ciclobutoxibenzil)-8isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
148 continua
- (VII98)
- C25H29N7O2 459.24 460.4 (VIaq) (R)-8-isopropil-2(piperidina-3-iloxi)-N-(2(piridina-2iloxi)benzil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII99)
- C24H33N7O4S 515.23 516.4 (VIar) (R)-8-isopropil-N-(2(morfolinosulfonil)benzil)2-(piperidina-3iloxi)pirazolo[1,5-a] [1, 3,5]triazina-4amina
- (VII100)
- C20H25BrN6O 444.13 445.3 (VIas) (R)-N-(2-bromobenzil)-8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII101)
- C21H27ClN6O 414.19 415.3 (VIat) (R)-N-(4-cloro-2metilbenzil)-8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII102)
-
C21H24ClF3N6O
468.17
469.3
(VIau)
R)-N-(4-cloro-2(trifluorometil)benzil)-8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
imagen144
- (VII103)
- C20H24Cl2N6O 434.14 435.3 (VIav) (R)-N-(2,3-diclorobenzil)-8isopropil-2-(piperidina3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
149 continua
- (VII104)
- C21H29N7O3S 459.21 460.4 (VIaw) (R)-2-(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5-a][1,3,5] triazina-4il)amino)metil)-Nmetilbenzenosulfonamida
- (VII105)
- C23H33N7O3S 487.24 488.4 (VIax) (R)-N-isopropil-2-(((8isopropil-2-(piperidina-3iloxi)pirazolo[1,5-a][1,3,5] triazina-4il)amino)metil)benzenosul fonamida
- (VII106)
- C24H33N7O3S 499.24 500.4 (VIay) (R)-8-isopropil-2(piperidina-3iloxi)-N-(2-(pirrolidina-1ilsulfonil)benzil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII107)
- C25H36N8O3S 528.26 529.4 (VIaz) (R)-8-isopropil-N-(2-((4metilpiperazina-1il)sulfonil)benzil)-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII108)
- C22H29N7O2 423.24 424.5 (VIba) (R)-2-(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)-Nmetilbenzamida
- (VII109)
-
C25H31N7O2
461.25
462.5
(VIbc)
N-(but-3-yn-2-il)-2-(((8isopropil-2-((R)-piperidina3-iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)benzamida
imagen145
- (VII110)
- C24H34N8O2 466.28 467.5 (VIbd) (R)-1-(2-(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil)-3propilurea
150 continua
- (VII111)
- C27H32N8O2 500.26 501.4 (VIbe) (R)-1-(2-(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil)-3fenilurea
- (VII112)
- C27H38N8O2 506.31 507.5 (VIbf) (R)-1-ciclohexil-3-(2(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5-a][1, 3,5]triazina-4il)amino)metil)femil)urea
- (VII113)
-
C28H34N8O2
514.28
515.4
(VIbg)
(R)-1-benzil-3-(2-(((8isopropil-2-(piperidina3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil)urea
imagen146
- (VII114)
- C23H32N8O2 452.26 453.5 (VIbh) (R)-1-etil-3-(2-(((8isopropil-2-(piperidina3iloxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil)urea
- com pues to
- Fórmula Calcula do MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VII115)
- C25H36N6O2 452.29 453.4 (VI-bj) (R)-N-(2-isobutoxi-4metilbenzil)-8isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII116)
- C23H30N6O3 438.24 439.4 (VI-bk) (R)-N-((3,4-dihidro2Hbenzo[b][1,4]dioxepi na-6il)metil)-8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII117)
- C26H34N60 446.28 447.4 (VI-bl) (R)-8-isopropil-2(piperidina-3-iloxi)N-((2’,3’,4’,5’tetrahidro-[1,1’bifenil]-2il)metil)pirazolo[1, 5a][1,3,5]triazina-4amina
151 continua
- (VII118)
- C21H28N6OS 412.20 413.3 (VIbm) (R)-8-isopropil-N-(2(metiltio)benzil)2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII119)
- C25H34N6OS 466.25 467.4 (VI-bj) (R)-N-(2(ciclopentiltio)benzil)-8isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
- (VII120)
- C23H26N8O 430.22 453.1 [M+Na]+ (VI-ba) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-((1,2,3,6tetrahidropiridina-3il)oxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII121)
- C26H32N8O2 488.26 489.2 (VI-a) 2-(1-oxa-8azaspiro[4.5]decan-3iloxi)-N-(2-(1H-pirazol-1il)benzil)-8isopropilpirazolo[1,5a][1,3,5]triazina-4-amina
- (VII122)
- C23H28N802 448.23 449.2 (VI-a) 2-((1,4-oxazepano-6il)oxi)-N-(2-(1H-pirazol-1il)benzil)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
- (VII123)
-
C24H28N8O
444.24
445.2
(VI-a)
N-(2-(1H-pirazol-1il)benzil)-2-((1R,5S)-3azabiciclo[3.2.0]heptano6-iloxi)-8isopropilpirazolo[1, 5a][1,3,5]triazina-4-amina
imagen147
- (VI I124)
- C24H31N9O 461.27 462.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2-(piperazin-1il)etoxi)pirazolo[1,5a][1,3,5]triazina-4-amina
152 continua
- (VI I125)
-
C24H28N8O
444.24
445.3
(VIa)
N-(2-(1H-pirazol-1-il)benzil)2-(2azabiciclo[2.2.1]heptano-5iloxi)-8isopropilpirazolo[1, 5a][1,3,5]triazina-4-amina
imagen148
- (VI I126)
- C20H25lN6O 492.11 493.2 (VIbo) N-(2-iodobenzil)-8-isopropil2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII127)
- C25H37N7O2S 499.2 500.3 (XIX) N-(2-(((8-isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil)-2metilpropano-2sulfinamida
- (VII128)
- C26H37N7O3 495.3 496.4 (XIX) (2-(((8-isopropil-2-((1metilpiperidina-4il)oxi)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil)carbamato de isobutilo
- (VII129)
- C24H3ON80 446.2 447.2 (VIbp) (R)-N-(2-((1H-pirazol-1il)metil)benzil)-8isopropil-2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII130)
-
C20H24Cl2N6O
434.1
435.2
(VIbq)
(R)-N-(2,5-diclorobenzil)-8isopropil-2-(piperidina3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
imagen149
- (VII131)
- C24H33N7O 435.2 7 436.3 (VIbr) (R)-8-isopropil-2-(piperidina3iloxi)-N-(2-(pirrolidina-1il)benzil)pirazolo[1, 5a][1,3,5]triazina-4-amina
153 continua
- (VII132)
-
C25H35N7O
449.2 9
450.4
(VIbs)
(R)-8-isopropil-N-(2(piperidina-1-il)benzil)2-(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4amina
imagen150
- (VII133)
- C25H31N9O3 505.2 5 506.2 (VIa) carbamato de azetidin3-il (2-((4-((2-(1 Hpirazol-1il)benzil)amino)-8isopropilpirazolo[1, 5a][1,3,5]triazina-2il)oxi)etil)(metilo)
- (VII134)
-
C26H37N9O3S
555.2 7
556.1
(VIa)
N-(2-((4-((2-(1Hpirazol-1il)benzil)amino)-8isopropilpirazolo[1, 5a][1,3,5]triazina-2il)oxi)etil)-3(dimetilamino)-Nmetilpropano-1sulfonamida
imagen151
- (VII135)
- C26H35N9O3S 553.2 6 554.0 (VIa) N-(2-((4-((2-(1Hpirazol-1il)benzil)amino)-8isopropilpirazolo[1, 5a][1,3,5]triazina-2il)oxi)etil)-Nmetilpiperidine-4sulfonamida
- (VII136)
- C24H29N9O3 491.2 4 492.4 (VIa) 2-((4-((2-(1H-pirazol-1il)benzil)amino)-8isopropilpirazolo[1, 5a][1,3,5]triazina-2il)oxi)etil azetidin-3-ilcarbamato
- (VII137)
- C24H31N9O3S 525.2 3 526.3 (VIa) 2-((4-((2-(1H-pirazol-1il)benzil)amino)-8isopropilpirazolo[1, 5a][1,3,5]triazina-2il)oxi)-N-(pirrolidina-3il)etanosulfonamida
154 continua
- (VII138)
- C25H30N8O 458.2 5 459.2 (VIa) N-(2-(1H-pirazol-1il)benzil)-2-(8azabiciclo[3.2.1]octan-3iloxi)-8isopropilpirazolo[1, 5a][1,3,5]triazina-4-amina
- (VII139)
- C24H28N8O 444.2 4 445.2 (VIa) N-(2-(1H-pirazol-1il)benzil)-2-(2azaespiro[3.3]heptano-5iloxi)-8isopropilpirazolo[1, 5-a][1,3,5]triazina-4amina
- (VII140)
- C24H30N8O 446.2 5 447.2 (VIa) N-(2-(1H-pirazol-1il)benzil)-2-((4aminociclohexil)oxi)-8isopropilpirazolo[1,5a][1,3,5]triazina-4-amina
- (VII141)
- C21H24N8O 404.2 1 405.2 (VIa) N-(2-(1H-pirazol-1il)benzil)-2-(azetidina-3iloxi)-8isopropilpirazolo[1, 5a][1,3,5]triazina-4-amina
155
Método J: Acoplamientos transversales C-C con el intermedio (XXIII) Compuesto (VII-141): N-(2-ciclobutilbenzil)-8-isopropil-2-(piperidin-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4
[0266] A una solución de 40 mg (0.068 milimoles) de yodo (XXIII) (preparada a partir del intermedio (VI-bo) en forma similar al método C sin el paso final de Boc-desprotección) en 0.5 mililitros de tolueno se agregan 5.4 miligramos (0.0068 mmol) de dicloro[1,3-bis(2,6-di-3-pentilfenil)imidazol-2-ilideno](3-cloropiridil)-paladio(II). Se desgasificó con nitrógeno y se agregó en forma de gotas 0.544 ml (0.272 mmol) de una solución de bromuro de ciclobutilzinc (0.5 M en THF) a 0 °C. El baño de hielo fue removido y la mezcla de la reacción fue agitada durante 90 minutos a la temperatura del cuarto. El producto intermedio fue purificado por medio de cromatografía de columnas (12 g de gel de sílice, ciclohexano/acetato etílico). El grupo Boc-protector fue removido con un 20% de TFA/DCM y el compuesto fue obtenido después de RP-HPLC utilizando un gradiente de agua/acetonitrilo (0.1 por ciento de TFA). MS (ES) C24H32N6O requiere 420.26, encontrado 421.2 (M+H)+.
Compuestos (VII-141) -(VII-144)
[0267] Los compuestos (VII-142)-(VII-144) fueron sintetizados en una forma similar al método J.
- Compuesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VII-141)
- C24H32N6O 420.26 421.2 (XXIII) (R)-N-(2ciclobutilbenzil)-8isopropil-2-(piperidin-3iloxi)pirazolo[1, 5a][1,3,5]triazina-4-amina
- (VII-142)
-
C25H34N6O
434.28
435.2
(XXIII)
(R)-N-(2ciclopentilbenzil)-8isopropil-2-(piperidin-3iloxi)pirazolo[1, 5a][1,3,5]triazina-4-amina
imagen153
- (VII-143)
- C23H30N6O 406.52 407.4 (XXIII) N-(2-ciclopropilbenzil)-8isopropil-2-(piperidina-3iloxi)pirazolo[1, 5a][1,3,5]triazina-4-amina
- (VII-144)
- C26H36N6O 448.30 449.4 (XXIII) (R)-N-(2-ciclohexilbenzil) -8-isopropil-2(piperidina-3iloxi)pirazolo[1, 5a][1,3,5]triazina-4-amina
156
- compuesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VII-145)
-
C22H28N6O3
424.22
425.4
(XXV) y cloruro de acetilo
Acetato de fenilo de (R)-2-(((8isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina4il)amino)metilo)
imagen155
- (VII-146)
- C23H31N7O3 453.25 454.4 (XXV) e isocianato de etilo Etilcarbamato de fenilo de (R)-2(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina4il)amino)metilo)
- (VII-147)
- C21H28N6O4S 460.19 461.3 (XXV) y cloruro de sulfonilo de metano Metanosulfonato de fenilo de (R)2-(((8-isopropil2-(piperidin-3iloxi)pirazolo[1,5a][1,3,5]triazina4il)amino)metilo)
- (VII-148)
- C24H34N6O3S 486.24 487.4 (XXV) y cloruro de terc-butilsulfinilo 2-metilpropano2-sulfinato de fenilo de 2-(((8isopropil-2-((R)piperidina-3iloxi)pirazolo[1, 5a][1,3,5]triazina4il)amino)metilo)
- (VII-149)
- C25H34N6O4 482.26 483.4 (XXV) y cloroformiato de isobutilo Carbonato de (fenilo de 2-(((8isopropil-2(piperidina-3iloxi)pirazolo[1, 5a][1,3,5]triazina4il)amino)metilo)) de (R)-isobutilo
- (VII-150)
- LDC191336 382.21 383.3 (XXV) Fenol de (R)-2(((8-isopropil-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina4il)amino)metilo)
158
MS (ES) C21H28N6O2S requiere 428.20, encontrado 429.2 (M+H)+.
[0279] Los compuestos (VII-152)-(VII-154) fueron sintetizados en forma similar al método O. En los casos en que se desean al sulfonilo relacionado en vez del sulfinilo, equivalentes adicionales de mCPBA fueron utilizados a temperaturas elevadas.
- Compuesto
- Fórmula Calculado MS(ES) [M+H]+ Nombre Estructura
- (VII-154)
-
C21H28N6O3S
444.19
445.4
(R)-8-isopropil-N-(2(metilsulfonil)benzil)-2(piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
imagen157
- (VII-152)
- C21H28N6O2S 428.20 429.2 8-isopropil-N-(2(metilsulfinil)benzil)-2-((R)piperidina-3iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
- (VII-153)
- C25H34N6O2S 482.25 483.3 N-(2(ciclopentilsulfinil)benzil)-8isopropil-2-((R)-piperidina3-iloxi)pirazolo[1,5a][1,3,5]triazina-4-amina
160
- Comp uesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VIII01)
- C23H29N9 431.25 432.4 (VI-a) N4-(2-(1H-pirazol-1il)benzil)-8-isopropilN2-(piperidina-3il)pirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII02)
- C24H29N9 443.25 444.1 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,6diazaespiro[3.4]octan -2-il)pirazolo[1,5a][1,3,5]triazin-4amina
- (VIII03)
- C25H31N9 457.27 458.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,7diazaespiro[4.4]nona no-2-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII04)
- C25H31N9 457.27 458.3 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(1,6diazaespiro[3.5]nona no-1-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII05)
- C25H31N9 457.27 458.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,6diazaespiro[3.5]nona no-2-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII06)
- C26H33N9 471.29 472.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,6diazaespiro[4.5]decan o-2-il)pirazolo[1,5a][1,3,5]triazina-4amina
162 163 164 165 166 167 168 169 170
- (VIII-07)
- C24H29N9 443.25 444.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,6diazaespiro[3.4]octan o-6-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-08)
-
C23H27N9
429.24
530.1
(VI-a)
N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(1,6diazaespiro[3.3]hept ano-1-il)pirazolo[1,5a][1,3,5]triazina-4amina
imagen159
- (VIII-09)
- C26H33N9 471.29 572.1 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,8diazaespiro[4.5]deca n-8-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-10)
- C23H27N9 429.24 530.0 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,6diazaespiro[3.3]hept ano-2-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-11)
-
C26H33N9
471.29
472.4
(VI-a)
N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(1,8diazaespiro[4.5]deca no-8-il)pirazolo[1,5a][1,3,5]triazina-4amina
imagen160
- (VIII-12)
-
C25H31N9
457.27
458.4
(VI-a)
N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,7diazaespiro[3.5]nona no-2-il)pirazolo[1,5a][1,3,5]triazina-4amina
imagen161
- (VIII-13)
- C25H31N9 457.27 458.3 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(1,7diazaespiro[4.4]nona no-1-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-14)
- C27H35N9 485.30 486.5 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(2,8diazaespiro[5.5]undecano2-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-15)
- C27H35N9 485.30 486.4 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(1,8diazaespiro[5.5]undecano8-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-16)
- C25H31N9 457.27 458.4 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(2,7diazaespiro[3.5]nonano-7il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-17)
- C25H31N9 457.27 458.5 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(1,7diazaespiro[4.4]nonano-7il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-18)
- C25H33N11 487.29 488.5 (VI-j) 8-isopropil-N-(2-(1-metil1H-tetrazol-5-il)benzil)-2(1,8diazaespiro[4.5]decano-8il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-19)
- C25H33N11 487.29 488.5 (VI-t) 8-isopropil-N-(2-(2-metil2H-tetrazol-5-il)benzil)-2(1,8diazaespiro[4.5]decano-8il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-20)
-
C25H31N9
457.27
458.2
(VI-a)
N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(1,7diazaespiro[3.5]nonano-7il)pirazolo[1,5a][1,3,5]triazina-4amina
imagen162
- (VIII-21)
- C27H35N9 485.30 486.5 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(2,9diazaespiro[5.5]undecano2-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-22)
- C26H33N9 471.29 472.3 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(1,8diazaespiro[4.5]decano-1il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-23)
- C27H35N9 485.30 486.4 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(1,9diazaespiro[5.5]undecano9-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-24)
- C25H33N9 459.29 460.3 (VI-a) N-(2-(1H-pirazol-1il)benzil)2-(4(dimetilamino)piperidina1-il)-8isopropilpirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII-25)
-
C24H31N9
445.27
446.3
(VI-a)
N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(4(metilamino)piperidina-1il)pirazolo[1,5a][1,3,5]triazina-4-amina
imagen163
- (VIII-26)
- C27H35N9 485.30 486.3 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(3,9diazaespiro[5.5]undecano3-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-27)
- C26H33N9 471.29 472.3 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(2,7diazaespiro[4.5]decano-2il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-28)
- C24H29N9 443.25 444.3 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(1,6diazaespiro[3.4]octano-1il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-31)
- C22H31N7O 409.26 409.9 (VI-c) 8-isopropil-N4-((S)-1-(2metoxifenil)etil)-N2-((R)piperidina-3il)pirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII-32)
- C23H33N7O 423.28 424.2 (VI-e) (R)-N4-(2isopropoxibenzil)-8isopropil-N2-(piperidina-3il)pirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII-33)
- C22H28N10 432.25 433.4 (VI-g) (R)-N4-(2-(1H-1,2,4triazol-1-il)benzil)-8isopropil-N2-(piperidina-3il)pirazolo[1,5a][1,3,5]triazina-2,4diamina
- compuesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (VIII-34)
- C25H31N9 457.27 458.4 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(1,7diazaespiro[3.5]nonano-1il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-35)
- C25H36N8O2S 512.26 513.4 (VI-u) 2-(((8-isopropil-2-(1,8diazaespiro[4.5]decan -8il)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)-N, Ndimetilbencenosulfon amida
- (VIII-36)
- C23H29N9O 447.25 448.4 (VI-q) N(benzo[c][1,2,5]oxadi azol-4-ilmetil)-8isopropil-2-(1,8diazaespiro[4.5]decan o-8-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-37)
- C26H33N9 471.29 472.5 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(2,8diazaespiro[4.5]decan o-2-il)pirazolo[1,5a][1,3,5]triazina-4amina
- (VIII-38)
- C27H36N8O 488.30 489.5 (VI-s) 1-(2-(((8-isopropil-2(1,8diazaespiro[4.5]decan o-8il)pirazolo[1,5a][1,3,5]triazina-4il)amino)metil)fenil) pirrolidin-2-ona
- (VIII-39)
- C21H27N9 405.24 406.2 (VI-a) N4-(2-(1H-pirazol-1il)benzil)-N2-(3aminopropil)-8isopropilpirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII-40)
- C24H31N9 445.27 446.3 (VI-a) N4-(2-(1H-pirazol-1il)benzil)-8-isopropilN2-(2-(pirrolidin-1il)etil)pirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII-41)
- C25H29F2N9 493.25 494.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-2-(3-(3,3difluoropirrolidina-1il)azetidina-1-il)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
- (VIII42)
-
C25H33N9O
475.28
476.2
(VIa)
N4-(2-(1H-pirazol-1il)benzil)-8-isopropilN2-metil-N2-(2morfolinoetil)pirazolo[1, 5-a][1,3,5]triazina-2,4diamina
imagen164
- (VIII43)
- C22H27N9 417.24 418.2 (VIa) N4-(2-(1H-pirazol-1il)benzil)-8-isopropilN2-(pirrolidina3-il)pirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII44)
- C25H33N9O 475.28 476.2 (VIa) N4-(2-(1H-pirazol-1il)benzil)-8-isopropilN2-(3morfolinopropil)pirazol o[1,5-a][1,3,5]triazina2,4diamina
- (VIII45)
- C25H33N9 459.29 460.3 (VIa) N4-(2-(1H-pirazol-1il)benzil)-8-isopropilN2-metil-N2-(2(pirrolidin-1il)etil)pirazolo[1,5a][1,3,5]triazina2,4-diamina
- (VIII46)
- C24H31N9O 461.27 462.2 (VIa) N4-(2-(1H-pirazol-1il)benzil)-8-isopropilN2-(2morfolinoetil)pirazolo[1, 5-a][1,3,5]triazina-2,4diamina
- (VIII47)
- C25H29N9O 471.25 472.1 (VIa) 1-(1-(4-((2-(1H-pirazol1-il)benzil)amino)-8isopropilpirazolo[1,5a][1,3,5]triazina-2il)azetidina-3il)pirrolidina-2-ona
- (VIII48)
- C22H29N9O 435.25 436.2 (VIa) N4-(2-(1H-pirazol-1il)benzil)-N2-(2-(2aminoetoxi)etil)-8isopropilpirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII49)
- C27H37N9 487.32 488.2 (VI-a) N4-(2-(1H-pirazol-1-il)benzil)-8-isopropil-N2metil-N2-(3-(piperidina1-il)propil)pirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII50)
- C24H29N9 443.25 444.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-2(hexahidropirrolo[3,4b]pirrol-5(1H)-il)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
- (VIII51)
-
C20H25N9
391.22
392.2
(VI-a)
N4-(2-(1H-pirazol-1il)benzil)-N2-(2aminoetil)-8isopropilpirazolo[1,5a][1,3,5]triazina-2,4diamina
imagen165
- (VIII52)
-
C23H29N9
431.25
432.2
(VI-a)
N4-(2-(1H-pirazol-1-il)benzil)-8-isopropil-N2(pirrolidina-3ilmetil)pirazolo[1,5a][1,3,5]triazina-2,4diamina
imagen166
- (VIII53)
- C23H29N9 431.25 432.1 (VI-a) N-(2-(1H-pirazol-1il)benzil)-2-(3aminopiperidina-1-il)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
- (VIII54)
-
C22H27N9
417.24
418.2
(VI-a)
N-(2-(1H-pirazol-1il)benzil)-2-(3aminopirrolidina-1-il)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
imagen167
- (VIII55)
- C22H27N9O2 449.23 450.2 (VI-a) 2-((4-((2-(1H-pirazol-1il)benzil)amino)-8isopropilpirazolo[1,5a][1,3,5]triazina-2il)amino)-3aminopropanoate de metilo
- (VIII56)
- C26H29N9 467.25 468.2 (VI-a) N4-(2-(1H-pirazol-1il)benzil)-N2-(2-amino-1feniletil)-8isopropilpirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII57)
- C23H29N9 431.25 432.2 (VI-a) N4-(2-(1H-pirazol-1il)benzil)-N2-(azetidina-3ilmetil)-8isopropil-N2metilpirazolo[1,5a][1,3,5]triazina-2,4diamina
- (VIII58)
- C25H33N9O 475.28 476.2 (VI-a) N4-(2-(1H-pirazol-1-il)benzil)-8-isopropil-N2-metil-N2-(2morfolinoetil)pirazolo[1,5a][1,3,5]triazina-2,4-diamina
- (VIII59)
- C23H29N9 431.25 432.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-2-(4aminopiperidina-1-il)-8isopropilpirazolo[1,5a][1,3,5]triazina-4-amina
- (VIII60)
- C24H31N9 445.27 446.2 (VI-a) N4-(2-(1H-pirazol-1il)benzil)-N2-(4aminociclohexil)-8isopropilpirazolo[1,5a][1,3,5]triazina-2,4-diamina
- (VIII61)
- C28H38N10O2 546.32 547.2 (VI-a) N-(2-(2-((4-((2-(1H-pirazol1-il)benzil)amino)-8isopropilpirazolo[1,5a][1,3,5]triazina-2il)amino)etoxi)etil)-2(pirrolidina-1-il)acetamida
- Compuesto
- Fórmula Calculado MS(ES) [M+H]+ Material inicial Nombre Estructura
- (X-1)
- C23H28N8OS 464.21 465.1 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil2-(piperidina-4ilsulfinil)pirazolo[1,5a][1,3,5]triazina-4amina
- (X-2)
- C24H28N6OS2 480.18 481.7 (VI-d) 8-isopropil-2(piperidina-4ilsulfinil)-N-(2-(tiofen2il)benzil)pirazolo[1,5a][1,3,5]triazina-4amina
- (X-3)
- C26H30N6OS 474.22 475.3 (VI-b) N-([1,1’-bifenil]-2ilmetil)-8-isopropil-2(piperidina-4ilsulfinil)pirazolo[1,5a][1,3,5]triazina-4amina
- (X-4)
- C22H27N9OS 465.21 466.0 (VI-g) N-(2-(1H-1,2,4triazol-1-il)benzil)-8isopropil2-(piperidina-4ilsulfinil)pirazolo[1,5a][1,3,5]triazina-4amina
- (X-5)
- C24H30N8OS 478.23 479.2 (VI-h) 8-isopropil-N-(2-(2metil-1H-imidazol-1il)benzil)2-(piperidina-4ilsulfinil)pirazolo[1,5a][1,3,5]triazina-4amina
- (X-6)
- C23H28N8OS 464.21 465.3 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2-((R)-((R)piperidina-3il)sulfinil)pirazolo[1,5a][1,3,5]triazina-4amina
173 174
- (X-7)
- C23H28N8O2S 480.21 481.1 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(piperidina-4ilsulfonil)pirazolo[1,5a][1,3,5]triazina-4amina
- (X-8)
- C23H28N8S 448.22 449.1 (VI-a) (R)-N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(piperidina3-iltio)pirazolo[1,5a][1,3,5]triazina-4amina
- (X-9)
- C23H28N8S 448.2 449.2 (VI-a) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(piperidina-4iltio)pirazolo[1,5a][1,3,5]triazina-4amina
- Com pues to
- Fórmula Calculado MS(ES) [M+H]+ Del intermedio Nombre Estructura
- (X11-
- C25H31N9O 473.27 474.1 (XI) 4-((2-(1H-pirazol-1
- 1)
-
il)benzil)amino)-8isopropil-N(piperidina4-ilmetil)pirazolo[1, 5a][1,3,5]triazina-2carboxamida
imagen173
- (X11-
- C23H27N9O 445.23 446.0 (XI) 4-((2-(1H-pirazol-1
- 2)
- il)benzil)amino)-N(azetidina-3-ilmetil)8-isopropilpirazolo[1, 5-a][1,3,5]triazina-2carboxamida
- (X11-
- C24H29N9O 459.25 460.1 (XI) 4-((2-(1H-pirazol-1
- 3)
- il)benzil)amino)-8isopropil-N(pirrolidina3-ilmetil)pirazolo[1, 5a][1,3,5]triazina-2carboxamida
- (X11-
- C25H31N9O 473.27 474.1 (XI) 4-((2-(1H-pirazol-1
- 4)
-
il)benzil)amino)-8isopropil-N(piperidina3-ilmetil)pirazolo[1, 5a][1,3,5]triazina-2carboxamida
imagen174
- (XII-
- C23H29N9O 447.25 448.1 (XI) 4-((2-(1H-pirazol-1
- 5)
- il)benzil)amino)-N-(4aminobutil)-8isopropilpirazolo[1, 5a][1,3,5]triazina-2carboxamida
- (XII-
- C24H27N9O 457.23 458.1 (XXVII) (4-((2-(1H-pirazol-1
- 7)
- il)benzil)amino)-8isopropilpirazolo[1, 5-a][1,3,5]triazina-2il)(2,6diazaespiro[3.3]hepta no-2il)metanona
- (XII-
- C26H33N9O 503.28 504.3 (XXVII) 4-((2-(1H-pirazol-1
- 6)
- 2 il)benzil)amino)-8-isopropil-N-metil-N(2morfolinoetil)pirazolo[ 1,5-a][1,3,5]triazina-2carboxamida
178 179
- (XII-8)
- C26H33N9O 487.28 488.2 (XXVII) 4-((2-(1H-pirazol-1il)benzil)amino)-8-isopropil-N-metil-N(2-(pirrolidina-1il)etil)pirazolo[1,5a][1,3,5]triazina-2carboxamida
- (XII-9)
-
C23H27N9O
445.23
446.3
(XXVII)
(4-((2-(1H-pirazol-1il)benzil)amino)-8isopropilpirazolo[1,5a][1,3,5]triazina-2il)(piperazina-1il)metanona
imagen175
- (XII-10)
- C22H27N9O 433.23 434.3 (XXVII) 4-((2-(1H-pirazol-1il)benzil)amino)-N-(3aminopropil)-8isopropilpirazolo[1, 5a][1,3,5]triazina-2carboxamida
- (XII-11)
- C24H29N9O 459.25 460.3 (XXVII) (4-((2-(1H-pirazol-1il)benzil)amino)-8isopropilpirazolo[1, 5a][1,3,5]triazina-2il)(4-aminopiperidina1-il)metanona
- Com pues to
- Fórmula Calcul ado MS(ES) [M+H]+ Del intermedio Nombre Estructura
- (XXX
- C21H27N9 405.24 406.2 (XXIX) N1-((4-((2-(1H-pirazol
- -1)
- 1-il)benzil)amino)-8isopropilpirazolo[1,5a][1,3,5]triazina-2il)metil)etano1,2-diamina
- (XXX
- C26H35N9O 489.30 490.2 (XXIX) N-(2-(1H-pirazol-1
- -2)
- il)benzil)-8-isopropil-2(((3morfolinopropil)amino) metil)pirazolo[1,5a][1,3,5]triazina-4amina
- (XXX
- C26H35N9 473.30 474.3 (XXIX) N-(2-(1H-pirazol-1
- -3)
- il)benzil)-8-isopropil2-((metil(2-(pirrolidina1il)etil)amino)metil)piraz olo[1,5-a][1,3,5]triazina4-amina
- (XXX
- C25H33N9 459.29 460.2 (XXIX) N-(2-(1H-pirazol-1
- -4)
- il)benzil)-8-isopropil2-(((2-(pirrolidina-1il)etil)amino)metil)piraz olo[1,5a][1,3,5]triazina-4amina
- (XXX
- C25H33N9O 475.28 476.2 (XXIX) N-(2-(1H-pirazol-1
- -5)
-
il)benzil)-8-isopropil-2(((2morfolinoetil)amino)met il)pirazolo[1,5a][1,3,5]triazina-4amina
imagen178
- (XXX
- C28H39N9 501.33 502.2 (XXIX) N-(2-(1H-pirazol-1
- -6)
- il)benzil)-8-isopropil-2((metil(3-(piperidina-1il)propil)amino)metil)pir azolo[1,5a][1,3,5]triazina-4amina
- (XXX
- C26H31F2N9 507.27 508.2 (XXIX) N-(2-(1H-pirazol-1
- -7)
- il)benzil)-2-((3-(3,3difluoropirrolidina-1il)azetidina-1-il)metil)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
- (XXX
- C26H31N9O 485.27 486.2 (XXIX) 1-(1-((4-((2-(1H-pirazol
- -8)
- 1-il)benzil)amino)-8
- isopropilpirazolo[1,5
- a][1,3,5]triazina-2
- il)metil)azetidina-3
- il)pirrolidina-2-ona
182 183
- (XXX-9)
- C26H35N9O 489.30 490.2 (XXIX) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2-((4(2-metoxietil)piperazina1-il)metil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (XXX-10)
- C23H29N9 431.25 432.2 (XXIX) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2((pirrolidina-3ilamino)metil)pirazolo[1,5a][1,3,5]triazina-4-amina
- (XXX-11)
- C23H29N9 431.25 432.2 (XXIX) N-(2-(1H-pirazol-1il)benzil)-8-isopropil-2(piperazina-1ilmetil)pirazolo[1, 5a][1,3,5]triazina-4-amina
- (XXX-12)
- C24H31N9 445.27 446.2 (XXIX) N-(2-(1H-pirazol-1il)benzil)-2-(((azetidina-3ilmetil)(metil)amino)metil)8-isopropilpirazolo[1,5a][1,3,5]triazina-4-amina
- (XXX-13)
-
C29H40N10O2
560.33
561.3
(XXIX)
N-(2-(2-(((4-((2-(1 Hpirazol-1-il)benzil)amino)8isopropilpirazolo[1, 5a][1,3,5]triazina-2il)metil)amino)etoxi)etil)2-(pirrolidina-1il)acetamida
imagen179
- (XXX-14)
- C24H31N9 445.27 446.2 (XXIX) N-(2-(1H-pirazol-1il)benzil)-2-((4aminopiperidina-1il)metil)-8isopropilpirazolo[1,5a][1,3,5]triazina-4amina
Claims (4)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7 imagen8 imagen9 N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-((4-(2-metoxietil)piperazina-1-il)metil)pirazolo[1,5a][1,3,5]triazina-4-amina N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-((pirrolidina-3-ilamino)metil)pirazolo[1,5-a][1,3,5]triazina-4amina N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(piperazina-1-ilmetil)pirazolo[1,5-a][1,3,5]triazina-4-amina N-(2-(1H-pirazol-1-il)benzil)-2-(((azetidina-3-ilmetil)(metil)amino)metil)-8-isopropilpirazolo[1,5a][1,3,5]triazina-4-amina N-(2-(2-(((4-((2-(1H-pirazol-1-il)benzil)amino)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-2-il)metil)amino)etoxi)etil)-2(pirrolidina-1-il)acetamida N-(2-(1H-pirazol-1-il)benzil)-2-((4-aminopiperidina-1-il)metil)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-4amina 1-metilpirrolidina-3-il 4-((2-(1H-pirazol-1-il)benzil)amino)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-2-carboxilato 8-isopropil-N-(2-(S-metilsulfonimidoil)benzil)-2-((R)-piperidina-3-iloxi)pirazolo[1,5-a][1,3,5]triazina-4-amina 4-((2-(1H-pirazol-1-il)benzil)amino)-8-isopropilpirazolo [1,5-a][1,3,5]triazina-2-ol N-(2-(1 H-pirazol-1-il)benzil)-2-bromo-8-isopropilpirazolo [1,5-a][1,3,5]triazina-4-amina 2-(1H-pirazol-1-il)benzil(2-bromo-8-isopropil pirazolo[1,5-a][1,3,5]triazina-4-il)carbamato de terc-butilo N-(2-(1H-pirazol-1-il)benzil)-8-isopropil-2-(piperidina-3-ilmetil)pirazolo[1,5-a][1,3,5]triazina-4-amina N4-(2-(1H-pirazol-1-il)benzil)-8-isopropil-N2-metil-N2-(2-morfolinoetil)pirazolo[1,5-a][1,3,5]triazina2,4-diamina N-(2-(1H-pirazol-1-il)benzil)-2-(4-aminopiperidina-1-il)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-4-amina N4-(2-(1H-pirazol-1-il)benzil)-N2-(4-aminociclohexil)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-2,4-diamina N-(2-(2-((4-((2-(1H-pirazol-1-il)benzil)amino)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-2-il)amino)etoxi)etil)-2(pirrolidina-1-il)acetamida N4-(2-(1H-pirazol-1-il)benzil)-8-isopropil-N2-(2-(piperazina-1-il)etil)pirazolo[1,5-a][1,3,5]triazina-2,4-diamina N-(2-(1 H-pirazol-1-il)benzil)-2-(azetidina-3-iloxi)-8-isopropilpirazolo[1,5-a][1,3,5]triazina-4-amina -
- 5.
- Un compuesto de acuerdo a cualquiera de las reivindicaciones 1 a la 4 para su uso como un agente farmacéuticamente activo.
-
- 6.
- El uso de por lo menos un compuesto de acuerdo a cualquiera de las reivindicaciones 1 a la 4 para la preparación de una composición farmacéutica para la profilaxis y/o el tratamiento de enfermedades infecciosas, incluyendo a enfermedades oportunistas, enfermedades inmunológicas, enfermedades autoinmunes, enfermedades cardiovasculares, enfermedades de células proliferativas, inflamaciones, disfunción eréctil, enfermedades causadas por la supervivencia, diferenciación de proliferación anormales de células madre, e infartos.
-
- 7.
- El uso de acuerdo a la reivindicación 6, donde la enfermedad inefectiva que incluye a infecciones oportunistas es seleccionada de un grupo conformado de o que consiste del SIDA, infecciones de adenovirus, enfermedades de hidatidosis alveolar (AHD -Alveolar Hydatid Disease, equinococosis), amebiasis (infección de la entamoeba histolytica), infección de Angiostrongylus, la anisakiasis, el ántrax, la babesiosis (infección de Babesia), infección del Balantidium (balantidiasis), infección de Baylisascaris (lombriz intestinal del mapache), la esquistosomiasis, la infección de Blastocystis hominis (blastomicosis), Boreliosis, botulismo, diarrea Brainerd, la brucelosis, la EEB (encefalopatía espongiforme bovina), candidiasis, Capilariasis (infección capilar), CFS (síndrome de fatiga crónica -Chronic Fatigue Syndrome), la enfermedad de Chagas (Tripanosomiasis americana), varicela (virus de la varicela-zoster), la infección por Chlamydia pneumoniae, cólera, síndrome de fatiga crónica, CJD (enfermedad de Creutzfeldt-Jakob -Creutzfeldt-Jakob Disease), Clonorquiasis (infección de la Clonorchis), CLM (Larva migratoria cutánea -Cutaneous Larva Migrans, la infección por anquilostomas), coccidioidomicosis, conjuntivitis, virus Coxsackie A16 (la fiebre aftosa), criptococosis, la infección por criptosporidium (criptosporidiosis), mosquito Culex (vector del Virus del Oeste del Nilo), larva cutánea migratoria (CLM -Cutaneous Larva Migrans), ciclosporosis (infección debido a la Ciclospora), la cisticercosis (neurocisticercosis), infección por el citomegalovirus,El dengue / dengue, infección debido a Dipylidium (tenia de perros y gatos), el virus del Ébola, Fiebre hemorrágica, equinococosis (Hidatidosis alveolar), encefalitis, infección de la Entomoeba coli, infección dispar de la Entomoeba, infección de la Entomoeba hartmanni, infección de la Entomoeba histolytica (Amebiasis), infección por la Entomoeba polecki, enterobiasis (infección de lombrices intestinales), la infección por el enterovirus (no polio), infección del virus EpsteinBarr, infección por el Escherichia coli, infección transmitida por los alimentos, la fiebre aftosa, dermatitis por hongos, gastroenteritis, Enfermedad estreptocócica del Grupo A, Enfermedad estreptocócica del grupo B, la enfermedad de Hansen (lepra), Síndrome Pulmonar del Hantavirus, infestación de Piojos (pediculosis), infección por Helicobacter pylori, enfermedad hematológica, infección del henapivirus, la hepatitis (VHC, VHB), herpes zóster, infección por VIH, ehrlichiosis humana, infección por el virus de la parainfluenza humana, influenza, Isosporiasis (infección de la Isospora), fiebre de Lassa, Leishmaniasis, Kala-azar (Kala-azar, infección de Leishmania), lepra, piojos (piojos del cuerpo, piojos de la cabeza, piojos púbicos), la enfermedad de Lyme, la malaria, la fiebre hemorrágica de Marburgo, el sarampión, la meningitis, la meningitis inducida por micobacterias, enfermedades transmitidas por mosquitos, infección del Complejo Mycobacterium avium (MAC -Mycobacterium avium Complex), infección por Naegleria, infecciones nosocomiales, infección intestinal no patógena amebas, la oncocercosis (Ceguera de ríos), Opisthorciasis (infección de Opisthorcis), infección del parvovirus, la peste, la PCP (neumonía por Pneumocystis carinii -Pneumocystis carinii Pneumonia), la poliomielitis, la fiebre Q, la rabia, Virus Respiratorio Sincitial (VRS -Respiratory Syncytial Virus), fiebre reumática, fiebre del valle Rift, ceguera de río (oncocercosis),
206imagen10 imagen11 imagen12
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12157751.4A EP2634190A1 (en) | 2012-03-01 | 2012-03-01 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP12157751 | 2012-03-01 | ||
| PCT/EP2013/054224 WO2013128028A1 (en) | 2012-03-01 | 2013-03-01 | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2583231T3 true ES2583231T3 (es) | 2016-09-19 |
Family
ID=47757629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13707008.2T Active ES2583231T3 (es) | 2012-03-01 | 2013-03-01 | Derivados de triazol-triazina selectivos dependientes de inhibidores de ciclina quinasa |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9567345B2 (es) |
| EP (2) | EP2634190A1 (es) |
| JP (1) | JP6182549B2 (es) |
| KR (1) | KR101821452B1 (es) |
| CN (1) | CN104350054B (es) |
| AU (1) | AU2013224848B2 (es) |
| BR (1) | BR112014021189B1 (es) |
| CA (1) | CA2865946C (es) |
| DK (1) | DK2820020T3 (es) |
| ES (1) | ES2583231T3 (es) |
| HU (1) | HUE029264T2 (es) |
| IL (1) | IL234183A (es) |
| MX (1) | MX347359B (es) |
| RU (1) | RU2645347C2 (es) |
| SG (1) | SG11201405129RA (es) |
| WO (1) | WO2013128028A1 (es) |
| ZA (1) | ZA201406078B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| EP3129371B1 (en) * | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2966164C (en) | 2014-10-31 | 2023-10-17 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole compound |
| ES2899196T3 (es) * | 2015-03-09 | 2022-03-10 | Aurigene Discovery Tech Ltd | Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK |
| MX394157B (es) | 2015-06-15 | 2025-03-24 | Ube Corp | Derivado de dihidropirrolopirazol sustituido. |
| AU2016284638B2 (en) * | 2015-06-24 | 2020-01-23 | Curovir Ab | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| CN106432249B (zh) * | 2016-09-30 | 2018-12-04 | 陕西科技大学 | 一类吡咯并[2,1-f][1,2,4]三嗪母核化合物的合成及其医药用途 |
| EP3664806B1 (en) | 2017-08-09 | 2025-04-30 | Sanford Burnham Prebys Medical Discovery Institute | 3-PHENYL-PYRAZOLO[1,5-A]PYRIMIDINE-5-CARBOXILIC ACID DERIVATIVES AS APELIN (APJ) RECEPTOR AGONISTS FOR THE TREATMENT OF CARDIOVASCULAR, METABOLIC, CNS, OR INFECTIOUS DISEASES OR DISORDERS |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| CA3088347A1 (en) * | 2018-01-17 | 2019-07-25 | Glaxosmithkline Intellectual Property Development Limited | Pi4kiii.beta. inhibitors |
| US12606561B2 (en) | 2018-04-11 | 2026-04-21 | Qurient Co., Ltd. | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors |
| KR20200141487A (ko) * | 2018-04-11 | 2020-12-18 | 주식회사 큐리언트 | 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체 |
| BR112020020645A2 (pt) * | 2018-04-11 | 2021-01-12 | Qurient Co., Ltd. | Derivados farmaceuticamente aceitáveis de pirazol-triazina e/ou pirazol-pirimidina |
| US11517568B2 (en) | 2018-09-12 | 2022-12-06 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| US11364234B2 (en) | 2018-09-12 | 2022-06-21 | The Governing Council Of The University Of Toronto | Compounds and methods for treating nematode infections |
| CR20210287A (es) | 2018-11-01 | 2022-02-15 | Syros Pharmaceuticals Inc | Inhibidores de cinasa 7 dependiente de ciclina (cdk7) |
| EP3885347B1 (en) | 2018-11-14 | 2023-11-22 | UBE Corporation | Dihydropyrrolopyrazole derivative |
| CN110101703B (zh) * | 2019-05-06 | 2021-06-11 | 暨南大学 | Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用 |
| RU2713152C1 (ru) * | 2019-08-30 | 2020-02-04 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения хронической аллергической крапивницы на фоне описторхоза |
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| CN110950871B (zh) * | 2019-12-25 | 2022-05-17 | 陕西师范大学 | 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用 |
| CN116964061A (zh) * | 2020-12-21 | 2023-10-27 | 詹森药业有限公司 | 作为细胞周期蛋白依赖性激酶7(cdk7)抑制剂的三环嘧啶 |
| US20250281495A1 (en) * | 2021-02-25 | 2025-09-11 | Icahn School Of Medicine At Mount Sinai | Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease |
| CN116940577A (zh) * | 2021-03-09 | 2023-10-24 | 詹森药业有限公司 | 作为细胞周期蛋白依赖性激酶7(cdk7)抑制剂的三环吡啶 |
| US20250042903A1 (en) * | 2021-06-17 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| WO2023001061A1 (en) * | 2021-07-17 | 2023-01-26 | Jingrui Biopharma Co., Ltd. | Cdk7 selective inhibitors as anticancer agents |
| EP4377312A1 (en) | 2021-07-29 | 2024-06-05 | Syngenta Crop Protection AG | Pesticidally active fused bicyclic heteroaromatic compounds |
| US20250019382A1 (en) * | 2021-11-23 | 2025-01-16 | Origenis Gmbh | Novel inhibitors of cyclin-dependent kinases |
| CN114181217B (zh) * | 2022-01-10 | 2022-12-27 | 陕西师范大学 | 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用 |
| EP4493193A1 (en) * | 2022-03-18 | 2025-01-22 | Qurient Co., Ltd. | Cdk7 inhibitors for antiviral treatment |
| CN120712267A (zh) * | 2023-02-21 | 2025-09-26 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| HK1044334A1 (zh) * | 1999-02-01 | 2002-10-18 | Cv治疗公司 | 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂 |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| AR047969A1 (es) * | 2004-02-25 | 2006-03-15 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| CZ302122B6 (cs) * | 2009-01-28 | 2010-10-20 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující |
| FR2943058B1 (fr) * | 2009-03-11 | 2011-06-03 | Centre Nat Rech Scient | Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique. |
| CZ302711B6 (cs) * | 2009-06-03 | 2011-09-14 | Univerzita Palackého v Olomouci | Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující |
-
2012
- 2012-03-01 EP EP12157751.4A patent/EP2634190A1/en not_active Withdrawn
-
2013
- 2013-03-01 CN CN201380011917.5A patent/CN104350054B/zh active Active
- 2013-03-01 BR BR112014021189-2A patent/BR112014021189B1/pt active IP Right Grant
- 2013-03-01 AU AU2013224848A patent/AU2013224848B2/en active Active
- 2013-03-01 DK DK13707008.2T patent/DK2820020T3/en active
- 2013-03-01 JP JP2014559259A patent/JP6182549B2/ja active Active
- 2013-03-01 US US14/381,146 patent/US9567345B2/en active Active
- 2013-03-01 KR KR1020147027812A patent/KR101821452B1/ko active Active
- 2013-03-01 HU HUE13707008A patent/HUE029264T2/en unknown
- 2013-03-01 WO PCT/EP2013/054224 patent/WO2013128028A1/en not_active Ceased
- 2013-03-01 CA CA2865946A patent/CA2865946C/en active Active
- 2013-03-01 SG SG11201405129RA patent/SG11201405129RA/en unknown
- 2013-03-01 ES ES13707008.2T patent/ES2583231T3/es active Active
- 2013-03-01 EP EP13707008.2A patent/EP2820020B1/en active Active
- 2013-03-01 MX MX2014010494A patent/MX347359B/es active IP Right Grant
- 2013-03-01 RU RU2014139705A patent/RU2645347C2/ru active
-
2014
- 2014-08-19 IL IL234183A patent/IL234183A/en active IP Right Grant
- 2014-08-19 ZA ZA2014/06078A patent/ZA201406078B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865946C (en) | 2020-01-21 |
| HUE029264T2 (en) | 2017-02-28 |
| CN104350054A (zh) | 2015-02-11 |
| ZA201406078B (en) | 2016-08-31 |
| EP2820020A1 (en) | 2015-01-07 |
| US20150018329A1 (en) | 2015-01-15 |
| MX2014010494A (es) | 2015-04-08 |
| EP2820020B1 (en) | 2016-04-06 |
| KR101821452B1 (ko) | 2018-01-23 |
| SG11201405129RA (en) | 2014-09-26 |
| CN104350054B (zh) | 2017-06-13 |
| EP2634190A1 (en) | 2013-09-04 |
| JP6182549B2 (ja) | 2017-08-16 |
| CA2865946A1 (en) | 2013-09-06 |
| IL234183A (en) | 2016-11-30 |
| BR112014021189B1 (pt) | 2022-08-16 |
| KR20140131994A (ko) | 2014-11-14 |
| DK2820020T3 (en) | 2016-07-04 |
| RU2014139705A (ru) | 2016-04-20 |
| WO2013128028A8 (en) | 2014-10-02 |
| MX347359B (es) | 2017-04-06 |
| AU2013224848B2 (en) | 2017-06-29 |
| BR112014021189A2 (es) | 2017-06-20 |
| JP2015511952A (ja) | 2015-04-23 |
| AU2013224848A1 (en) | 2014-08-28 |
| US9567345B2 (en) | 2017-02-14 |
| HK1206014A1 (en) | 2015-12-31 |
| WO2013128028A1 (en) | 2013-09-06 |
| RU2645347C2 (ru) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2583231T3 (es) | Derivados de triazol-triazina selectivos dependientes de inhibidores de ciclina quinasa | |
| JP7810702B2 (ja) | 嚢胞性線維症膜コンダクタンス制御因子モジュレーター | |
| US6451804B1 (en) | Heteroalkylamino-substituted bicyclic nitrogen heterocycles | |
| AU652840B2 (en) | Imidazo(2,1-b)(3)benzazepine derivatives, compositions and method of use | |
| ES2702659T3 (es) | Derivado de tetrahidrociclopentapirrol y un método para prepararlo | |
| JP2019535689A5 (es) | ||
| TW200804389A (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
| WO2025049641A1 (en) | Kras modulators and uses thereof | |
| BR112020018983A2 (pt) | Inibidores de canal receptor de potencial transitório de oxadiazol | |
| UA121467C2 (uk) | Біциклічні анельовані гетероарильні або арильні сполуки та їх застосування як інгібіторів irak4 | |
| BRPI1012159A2 (pt) | derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase. | |
| CA3181790A1 (en) | Amidopyrimidone derivatives | |
| CZ20032416A3 (cs) | 6-Substituované pyridopyrimidiny | |
| AU2014234906A1 (en) | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| CN101918079A (zh) | 蛋白激酶抑制剂及其用途 | |
| JP7101685B2 (ja) | 新規jakキナーゼ阻害剤としての二環式アミン | |
| TW200918071A (en) | Agent for prevention and/or treatment of skin diseases | |
| CA3023379A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| BR112021005936A2 (pt) | moduladores de monoacilglicerol lipase | |
| CN111788200A (zh) | 酰亚胺衍生物和包含所述衍生物作为活性成分的杀菌剂 | |
| WO2009154870A1 (en) | Hiv integrase inhibitors | |
| TW201920184A (zh) | Cdpk1抑制劑、組合物及與其相關之方法 | |
| US10570129B2 (en) | Carboline antiparasitics | |
| US11771738B2 (en) | Endoparasitic depsipeptides |